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Abstract 
Involving healthcare consumers (HCCs) in clinical practice guideline (CPG) development 
can lead to identification of topics that guidelines should consider. To evaluate the strategies 
being used to involve HCCs in CPG development, a description of these strategies is needed. 
This study utilized qualitative description to analyze CPGs and related documents. 
Professionals involved in CPG development were also interviewed. Patients, family 
members, and informal caregivers have been involved in the formulation of 
recommendations, CPG reviewing and editing, and through use of patient resources. 
According to the results, involving HCCs is done to incorporate patient preferences and 
values into CPGs, and to improve their impact. By failing to provide opportunity for ongoing 
communication between stakeholders, some strategies may fail to ensure that input from 
HCCs is considered. Strategies being used will need to be evaluated in the future to ensure 
they are achieving the desired effects. 
Keywords 
patient and public involvement, healthcare consumers, clinical practice guideline, 
development, Canadian, qualitative description, mood disorders, anxiety disorders 
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Lay Summary 
Clinical practice guidelines (CPGs) are documents meant to advise healthcare providers on 
the most effective options for the management of illness. Involving patients, their family 
members, and members of the general public, collectively referred to as healthcare 
consumers (HCCs), in the process of developing CPGs may help in identifying important 
issues these documents should address. Involving HCCs in the development of CPGs can 
also help to make patients feel empowered, and help them work together with healthcare 
providers in decision making. In order to evaluate the effects of involving HCCs in CPG 
development, a descriptions of current strategies is needed. This study therefore investigated 
how and why HCCs have been involved in the development of CPGs for the management of 
mood and anxiety disorders within Canada. Clinical practice guidelines and documents 
describing their development were analyzed to find answers to the research question. 
Professionals involved in CPG development, including authors and research advisors, also 
contributed information through participating in interviews or completing questionnaires. 
Results of this study indicate that patient resources were created to accompany the CPGs 
analyzed for this study. Patient resources are tools such as decision aids or CPG summaries 
meant to advise patients or their loved ones on their treatment options. Since these CPGs 
were released, additional strategies have been used to involve different types of HCCs 
throughout different stages of CPG development. Results of this study also indicate that 
currently, HCCs are involved in CPG development in order to identify information or 
treatment outcomes that are important to patients. A greater focus on facilitating the 
partnership between patients and healthcare providers could help to increase HCC 
involvement in CPG development in the future. In addition, future efforts to involve HCCs in 
CPG development must ensure that input from these stakeholders is gathered in a way that 
ensures it is acted upon. 
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Chapter 1  
1 Introduction 
The benefits of involving healthcare consumers (HCCs) in clinical practice 
guideline (CPG) development include identifying information important to patients that 
should be incorporated into CPGs, helping to reduce the effects of professional biases, 
facilitating democratic decision making during CPG development, and empowering 
patients and other members of the public. How HCCs are involved is an important 
consideration for appraising what benefits can be achieved, or even how efficiently they 
are achieved. For example, involvement of HCCs in CPG development can be 
categorized by the direction of information flow between HCCs and professionals (Rowe 
& Frewer, 2005). Furthermore, the benefits and challenges encountered when involving 
HCCs in CPG development can depend on the type of HCC involved, the specific 
method used, and the stage of CPG development in which they are involved. Before we 
can evaluate the effectiveness of the strategies used to involve HCCs in CPG 
development, those strategies must first be documented and described (Armstrong & 
Bloom, 2017; Légaré et al., 2011). Such studies have been conducted outside of Canada 
with differing healthcare environments, and have not included Canadian CPGs or the 
practices used by Canadian CPG developers. This study seeks to address this gap by 
describing the strategies used to involve HCCs in CPG development within Canada. 
Because of its potential benefits, involving HCCs in the development of CPGs has 
been recognized as important in recent years. The United States National Academy of 
Medicine (formerly the Institute of Medicine [IOM]; IOM, 2011), The Guidelines 
International Network (GIN; GIN, 2015), World Health Organization (WHO, 2014) and 
the United Kingdom National Institute for Health and Care Excellence (NICE, 2014), 
among others, have recommended that HCCs, or patients specifically, be involved in the 
development of CPGs. In addition, tools meant to advise on the development of high-
quality CPGs, such as the Appraisal of Guidelines Research & Evaluation (AGREE) tool, 
recommend that HCCs be involved in CPG development. AGREE II, the latest iteration 
of the tool, asks guideline developers and evaluators to consider whether “the views and 
preferences of the target population (patients, public, etc.) have been sought” (Brouwers 
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et al., 2010). Despite the consensus that HCC involvement in CPG development can be 
beneficial, there is little agreement regarding best practices. A number of challenges exist 
that negatively impact the outcomes of HCC involvement in CPG development, and that 
may hinder its use (Légaré et al., 2011). The identification of the most effective strategies 
of HCC involvement in CPG development is needed to ensure the practice is used 
effectively.  
This research examines the involvement of HCCs in CPG development in 
Canada, specifically in CPGs created for the management of mood and anxiety disorders. 
Mood and anxiety disorders were chosen as a focus because they represent a prevalent 
class of illnesses within Canada; high-quality CPGs can assist in the management of 
these illnesses; and there are enough CPGs developed in this area to support an analysis. 
Within this context, this study seeks to answer the questions of who is being involved in 
CPG development in Canada, how this is happening, including the specific methods used 
and the stages at which it is occurring, and why HCCs are being involved. Characterizing 
the strategies used to involve HCCs in CPG development will allow these strategies to be 
tested in future studies, in order to appraise their effectiveness in achieving the purported 
benefits of HCC involvement, and to identify challenges that must be overcome to do so 
efficiently. 
This chapter provides important definitions utilized throughout this thesis, 
outlines the knowledge gap this study seeks to address, and provides a review of existing 
literature describing important concepts for this study. The relevance of this study to 
health information science, and the final research question are also provided. 
1.1 Definitions 
To provide context for this thesis, this section provides important definitions. 
Terms defined here include “healthcare consumer”, “professional”, and “clinical 
practice guideline”. 
For the purpose of this research, the term “healthcare consumer” (HCC) is 
defined as any lay persons who do or could receive services from the healthcare system. 
Healthcare consumers include patients, family members, informal caregivers, the general 
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public, and patient representatives (Armstrong & Bloom, 2017; Qaseem et al., 2012). 
Patients are individuals with current or past lived experience with a disease or illness. 
Family members are those individuals with a close relative experiencing or who has 
experienced a disease or illness, who may take at least partial responsibility for caring for 
the individual living with a disease or illness. The general public refers to lay individuals 
without personal experience of a disease or illness of interest, and without relation or 
connections to others with a disease or illness of interest. Patient representatives are 
individuals with experience with a disease or illness of interest, tasked with representing 
a group of patients or patient organization at in health policy and services decision-
making table. In addition, health care consumers include patient advocates. Patient 
advocates are professionals appointed to share knowledge regarding patient values within 
guideline development groups (Roth, 2011; Williamson, 1998). 
For this thesis, the term “professional” is defined as any individual with formal 
training or education within healthcare and health services and policy design, excluding 
patient advocates. Previous reviews of CPG development procedures have outlined that 
these can include, but are not limited to, general practitioners, medical specialists, 
pharmacists, nurses, nurse practitioners, and other healthcare providers. Professionals can 
also include methodologists, topic experts, and researchers (IOM, 2011; Qaseem, 2012).  
Finally, the definition of “clinical practice guideline” (CPG) used for this study is 
based on descriptions given by The American Academy of Family Physicians (2017), 
Davis and colleagues (2007) and the Institute of Medicine (2011). Clinical practice 
guidelines are defined as review documents that contain recommendations based on 
systematic review of available evidence and/or expert consensus, meant to inform 
primary care physicians, medical specialists, or allied health clinicians in the diagnosis, 
assessment, and treatment of illness. 
1.2 Literature Review 
This section provides an overview of current literature relevant to this study. First, 
an overview of the current use of HCC involvement in CPG development is provided. 
This section also outlines the potential benefits that make the practice important to 
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consider, evaluate, and improve to ensure these benefits are being achieved. A framework 
for categorizing how HCCs can be involved in the development of CPGs is also 
established. This includes explanations of consumer participation, consumer consultation, 
and consumer communication, as first described by Rowe & Frewer (2005). Strengths 
and weaknesses of each of these approaches are provided. This framework helps to guide 
data analysis in categorizing the strategies of HCC involvement encountered. Finally, 
additional factors likely to influence the effectiveness or outcomes of HCC involvement 
in CPG development are described. These factors include the type of HCC involved, the 
specific method used, and the stage of CPG development at which these methods are 
used. 
1.2.1 Current Use of Healthcare Consumer Involvement in Clinical 
Practice Guideline Development 
Internationally, HCCs have been involved in the development of CPGs in a wide 
variety of clinical areas. Légaré and colleauges (2011) characterized patient and public 
involvement programs within the United States, the United Kingdom, Germany, and 
Australia. These programs were used in the development of CPGs pertaining to the care 
of diabetes, stroke, cardiovascular diseases, kidney disease, and spinal chord injuries. Use 
of these programs was also found to be highly represented in CPGs developed for mental 
health and cancer (Légaré et al., 2011). Patients are the most common group of HCCs to 
be involved in CPG development. Results of the afformentioned study indicate that 
patients are involved in 63% of CPG development initiatives and family members or 
informal caregivers are involved in about 42% of these initiaitves (Légaré et al., 2011). 
This same study demonstrated that patients, family members, and informal caregivers are 
most often involved during the formulation of reccomendations, the process of 
knowledge synthesis, and during draft revision (Légaré et al., 2011).  
There remains some room for improvement in the prevalence of patient and 
public involvement programs in CPG development. Between 1994 and 1999, only 19.6% 
of Canadian CPG developers included patients or other HCCs in their CPG development 
committees (Graham et al., 2003). A more recent study conducted in the United States 
indicated that only 8% of CPG development groups require input from patients in that 
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country (Armstrong & Bloom, 2017). A review of practices used by guideline developers 
from Africa, Asia, Oceania, Western Europe, Latin America, and North America revealed 
that 29% of these groups require patient or public involvement in CPG development, and 
39% involve patients or the public only “when necessary” (Lavis, Paulsen, Oxman, & 
Moynihan, 2008). Results of these studies indicate that there remains some room for 
improvement in the use of patient and public involvement in CPG development, both 
within Canada and internationally. There is indication that use of the practice is 
increasing within Canada specifically, although this research does not describe recent 
trends. The aims of this study do not include providing a quantitative description of the 
prevalence of HCC involvement in CPG development. Instead, the aims of this study 
include providing a qualitative description of the strategies used to involve HCCs in CPG 
development in Canada. 
1.2.2 Benefits of Healthcare Consumer Involvement in Clinical 
Practice Guideline Development 
Involving HCCs in the development of CPGs has been described as beneficial for 
several distinct reasons. First, HCCs can bring additional perspectives and knowledge, in 
some cases gained through lived experience, to the CPG development process (van de 
Bovenkamp & Trappenburg, 2009). These perspectives can be important to consider 
because they may differ from those of healthcare professionals (Mühlbacher & Juhnke, 
2013; Roberge et al., 2016). For example, meta-analyses have provided evidence that 
adult patients prefer psychotherapy over pharmacological treatment for unipolar 
depression; however, pharmacotherapy remains the standard choice of clinicians for the 
treatment of depressive disorders (McHugh, Whitton, Peckham, Welge, & Otto, 2013; 
Roberge et al., 2016). In cases where scientific evidence offers some degree of choice in 
treatment alternatives, input from HCCs can help ensure that information and 
recommendations contained within CPGs reflect the preferences of patients. This helps to 
ensure that CPGs remain accountable to both patients and the public (Légaré et al., 2009).  
In addition, involving HCCs in CPG development can lead to the addition of 
valuable content, such as information regarding patient preferences and values, or to the 
identification of important topics CPGs should address (Armstrong et al., 2018). 
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Armstrong and colleagues (2018) conducted a parallel group study in which two groups 
were asked to create a CPG for the use of positron emission tomography in patients with 
dementia. In this study, the group that included patients identified the rate of progression 
of cognitive impairment as an important consideration for this guideline. This concern 
was not addressed by the group that excluded patients (Armstrong et al., 2018). In a 
similar study, Tong and colleagues (2012) conducted workshops with patients that led to 
the incorporation of a subtopic on “symptoms, natural history, and outcomes of chronic 
kidney disease” within a CPG pertaining to chronic kidney disease management. Input 
from HCCs during CPG development can also lead to the creation of additional 
resources, such as plain-language summaries meant to accompany guidelines (Tong et al., 
2012). In a study by Tong and colleagues (2012), consultation with a group of HCCs 
during CPG development prompted the creation of a plain English version of the 
guideline for the reference of lay people. Research has demonstrated that including 
patients in CPG development can influence both content and format. CPGs developed 
with the involvement of HCCs are therefore more likely to include issues that patients 
consider to be relevant. 
Some authors have suggested that knowledge and information contributed to CPG 
development by HCCs can lead to a greater focus on shared decision making and patient-
centered care in individual clinical consultations (Légaré et al., 2009). A focus on patient-
centered care in clinical consultations is associated with higher-quality decision making 
that results in improvements in health outcomes for patients (Ontario Medical 
Association, 2010). However, there remains little direct evidence to suggest that 
involving HCCs in CPG development will encourage the use of patient-centered care in 
individual clinical consultations. A Cochrane review assessed the effects of consumer 
involvement in developing healthcare policy and research, CPGs, and patient information 
material (Nilsen, Myrhaug, Johansen, Oliver, & Oxman, 2006). The authors concluded 
that there remains a “huge gap” in evidence about the desirable and undesirable effects of 
involving HCCs in healthcare decision making at the population level, including its 
effects on healthcare outcomes (Nilsen et al., 2006). A more recent study that included a 
review of CPGs and interviews with CPG developers, indicated that the focus on patient 
centered care in these documents is unlikely to improve with patient input (van de 
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Bovenkamp & Zuiderent-Jerak, 2015). These researchers did not conclude that patient 
participation in CPG development was therefore undesirable, but rather that the design of 
patient participation matters significantly in the outcome.  
Involving patients in the development of CPGs has been suggested as a method to 
help manage professional biases, potentially mitigating their effects on the final product. 
The National Academy of Medicine, in its comprehensive manual for the development of 
CPGs, recommends that patients and the public be involved in CPG development as a 
matter of transparency in order to “provide a window into the process and some 
assurance that guidelines were not developed ‘behind closed doors’ to suit special 
interests” (IOM, 2011, p. 89). In addition to improving transparency, patients may be able 
to resist recommendations that favor the self-interests of professionals (IOM, 2011). 
Professional endeavours, such as research, professional agency affiliations, or practice 
specialization, may influence professional input in CPG development (Ayanian, 
Landrum, Normand, Guadagnoli, & McNeil, 1998; Detsky, 2006; IOM, 2009). For 
example, physicians may be inclined to recommend a treatment that they have personally 
researched or developed, even if a wider body of evidence suggests the superiority of 
alternative treatments (Detsky, 2006). Physicians’ decision making during CPG 
development can also be influenced by their interactions with pharmaceutical companies, 
who may offer to provide training and funding to these physicians (Fickweiler, 
Fickweiler, & Urbach, 2017: IOM, 2011). Including patients at the guideline 
development table may allow them to bring their own interests back to the forefront of 
concern (Detsky, 2006). 
Finally, justification for involving HCCs in CPG development has also included 
“principles-based” arguments of improving accountability and empowerment, called the 
democratic model and consumerist model, respectively (GIN, 2015, van de Bovenkamp 
& Trappenburg, 2009). The democratic model posits that including patients in CPG 
development allows for democratic decision making, which enhances the accountability 
of the process (Florin & Dixon, 2004). The democratic model states that patients and the 
public should be included in health policy development, including the development of 
CPGs, as it represents a chance for citizens to fulfill their duty to contribute to society, 
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and allows diverse interests to be represented in the process (Boivin, Green, van der 
Meulen, Légaré, & Nolte, 2009; Wait & Nolte, 2006). Furthermore, some authors have 
suggested that substantive democracy requires deliberation between stakeholders, with 
deliberation entailing discussions that involve careful and serious weighing of reasons for 
and against some proposition (Abelson et al., 2003; Dryzek, 2000; Fearon, 1998). The 
consumerist model stresses the importance of HCC empowerment through providing 
these stakeholders with information and the chance to become active decision makers 
within the healthcare system (Wait & Nolte, 2006). Empowering HCCs through 
providing information and the opportunity for free choice allows for well-informed 
decision making in CPG development and a chance to remedy information asymmetry in 
healthcare (GIN Public Working Group, 2015; Wait & Nolte, 2006). Furthermore, 
involving HCCs in CPG development could help to shift the balance of power between 
stakeholders in the healthcare sector, to make patients and professionals more like 
partners (van de Bovenkamp & Trappenburg, 2009).  
Principles-based arguments have led advocates to describe HCC involvement in 
CPG development as a goal in itself (Rashid, Thomas, Shaw & Leng, 2017; van de 
Bovenkamp & Trappenburg, 2009). Authors advocating for HCC involvement in CPG 
development have suggested that principles-based arguments for HCC involvement in 
CPG development be brought to the forefront. However, these principles-based 
arguments, such as striving for a more representative democratic decision making process 
in the development of CPGs, have implications for the quality of CPGs being developed 
that can be described and potentially quantified. For example, empowering patients 
through involvement indicates that these individuals will become better educated on their 
healthcare and more likely to contribute to their design in the future (van de Bovenkamp 
& Trappenburg, 2009). Furthermore, making the process democratic should be done in 
order to stimulate debate, improve public understanding of complex healthcare issues, 
and produce consensus surrounding public and community values for health services 
priorities (Ableson et al., 2003).  
In summary, several benefits to involving HCCs in CPG development have been 
described in the literature. These benefits include facilitating the incorporation of 
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knowledge coming from HCCs, that can help to navigate through unclear scientific 
evidence, or to identify topics that should be incorporated into CPGs. Healthcare 
consumers might also be able to manage professional biases. Finally, “principles-based” 
reasons include the potential to facilitate democratic decision making, and to achieve 
HCC empowerment. There is growing evidence that the purported benefits of HCC 
involvement in CPG development are attainable; however, there remains a lack of 
evidence to suggest that the practice will lead to a greater focus on patient-centered care 
and the associated higher-quality decision making in clinical consultations. 
1.2.3 Types of Healthcare Consumer Involvement Strategies and 
Their Relevance 
Frameworks for involving patients and members of the public in healthcare 
service, policy, and research design have been described by Arnstein (1969) and by Rowe 
and Frewer (2005). These patient and public involvement frameworks can be applied to 
describe HCC involvement in the development of CPGs as a specific instance of health 
service design. Healthcare consumer involvement in health services design, including in 
the development of CPGs, has commonly been described in relation to a “ladder” of 
citizen involvement, as first described by Arnstein (1969). This ladder is divided into 
eight rungs of participation, according to the level of decision-making power that HCCs 
are afforded. These rungs are collected into broader groups of involvement that include 
“non-participation”, “tokenism”, and “citizen power”. Involvement at the non-
participation level includes initiatives meant to enable education of patients or the public 
(Arnstein, 1969). Tokenism includes initiatives in which patients and the public have the 
opportunity to receive education from professional stakeholders, but also have 
opportunity to provide their own input into the task at hand. However, at this level, there 
are no safeguards to ensure that input from patients or the public is incorporated into final 
decision making. Finally, initiatives at the level of citizen power allow patients and the 
public to obtain at least some decision-making power. This can be achieved through 
engaging in trade-offs with professionals, or through taking over managerial positions 
within these initiatives (Arnstein, 1969). Previous literature has argued that in order for 
patients or the public to affect decision making within health services design, research 
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and policy-development, the involvement of these stakeholders must reach the level of 
citizen power (Arnstein, 1969; Caron-Flinterman, Broerse, & Bunders, 2007; Elberse, 
Caron-Flinterman & Broerse, 2011). 
In a model related to Arnstein’s ladder of involvement, Rowe and Frewer (2005) 
described three categories of HCC involvement based on the flow of information between 
these stakeholders and professionals, called consumer participation, consumer 
consultation, and consumer communication (Armstrong & Bloom, 2017; GIN, 2015; 
Légaré et al., 2011). Consumer participation involves transfer of information between 
HCCs and professionals, while consumer consultation allows for the transfer of 
information from HCCs to professionals only. Finally, consumer communication allows 
only for the transfer of information from professionals to HCCs (Rowe & Frewer, 2005). 
Each of these approaches to HCC involvement offers unique benefits, but also come with 
their own challenges and shortcomings.  
In consumer participation, HCCs act as active members in CPG development 
groups, allowing for active and ongoing dialogue between researchers, policy makers, 
and HCCs throughout the process of guideline development (Armstrong & Bloom, 2017; 
Rowe & Frewer, 2005). The correspondence between professionals and HCCs that 
consumer participation allows for has been theorized to contribute to the formation of 
meaningful agreements (Rowe & Frewer, 2005). In practice however, consumer 
participation poses some challenges. Professionals often perceive direct engagement with 
HCCs as counterproductive because differences in opinion between HCCs and 
professionals can lead to conflicts that are difficult to resolve (van de Bovenkamp & 
Zuiderent‐Jerak, 2015). Healthcare consumers also experience problems when engaging 
in guideline development through consumer participation methods. Previous studies have 
shown that consumers contribute to dialogue within guideline development groups 
infrequently, often owing to perceived power imbalances between themselves and 
professionals (van Wersch & Eccles, 2001). Engaging directly as members of guideline 
development groups may also exacerbate issues regarding time commitments and the 
need for training (van de Bovenkamp & Trappenburg, 2009; van Wersch & Eccles, 
2001). 
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Consumer consultation involves collecting information on opinions, values, and 
perspectives from HCCs at key points in the guideline development process, without 
iterative or formal dialogue directly between HCCs and professional members of the 
guideline development group (Rowe & Frewer, 2005). Consumer consultation often 
involves gathering the perspectives of HCCs through use of focus groups or surveys. 
These methods offer cost effectiveness as a benefit. These methods also encourage 
contribution from HCCs through allowing a large number of consumers to be reached 
and through removing the effects of perceived power imbalances, since HCCs do not 
need to directly interact with professionals (Légaré et al., 2011; Tong et al., 2012). The 
decreased interaction between professionals and HCCs in consumer consultation methods 
also aids in minimizing conflict between these two groups (van de Bovenkamp & 
Zuiderent‐Jerak, 2015). However, the absence of ongoing dialogue between consumers 
and professionals may hinder the ability of professionals involved in CPG development 
to utilize information gathered from consumers and make guidelines that are acceptable 
to both groups (Rowe & Frewer, 2005). Even with this drawback, consumer consultation 
methods have been demonstrated to have a perceivable impact on developed guidelines, 
contributing to the creation of guidelines that are understandable to both clinicians and 
patients (Elwyn et al., 2017; Tong et al., 2012). 
In contrast to consumer consultation and consumer participation, consumer 
communication methods do not offer opportunity for transfer of information from HCCs 
to professionals; however, they offer the opportunity to educate HCCs (Guidelines 
International Network Public, 2015; Rowe & Frewer, 2005). These methods attempt to 
provide HCCs with information deemed beneficial for their awareness and 
comprehension of CPGs to improve outcomes of their use. Patient education, a main 
focus of consumer communication, has been recognized as an important aspect of patient 
empowerment and patient-centered care (Grol, 2001). In addition, consumer 
communication helps to establish the trustworthiness and accessibility of guidelines by 
making the development process transparent (Armstrong et al., 2018). Consumer 
communication methods typically involve HCCs at the stages of guideline dissemination 
and evaluation (Armstrong & Bloom, 2017). Methods of consumer communication such 
as use of educational tools and decision aids meant to accompany CPGs, have been 
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demonstrated to improve consumer knowledge of guidelines, improve control of the 
targeted illness, and improve use of under-utilized treatment options (Gagné, Légaré, 
Moisan, & Boulet, 2017; Taddio et al., 2013). These methods are also beneficial because 
they are cost effective and do not require large time commitments from consumers 
(Armstrong, Mullins, Gronseth, & Gagliardi, 2017). Because consumer communication 
involves providing patients with information only, these strategies, such as the use of 
patient resources, do not allow HCCs to provide input during CPG development that may 
influence the content of these tools. These strategies involve a one-way flow of 
information from professionals to consumers, with no channel to provide feedback and 
no power for negotiation.  
1.2.4 Important Aspects of Healthcare Consumer Involvement in 
Clinical Practice Guideline Development 
As evidence continues to accumulate pointing to its benefits, involvement of 
HCCs in the development of CPGs has been increasingly recognized as important by 
international authoritative organizations. While there is a general consensus that the 
practice can have meaningful impact on guideline development and content, there are 
many challenges that need to be overcome to ensure these efforts are successful. Studies 
at a multinational level have identified challenges that limit the use and usefulness of 
patient involvement in guideline development (Légaré et al., 2011). From the perspective 
of health care professionals, these challenges include eliciting and incorporating another 
set of views. Challenges are also faced by HCCs, such as managing time constraints, or 
experiencing resistance from professionals (Légaré et al., 2011).  
Authors have indicated that some of these challenges may be overcome simply by 
increasing efforts to include patients in CPG development on both national and 
international scales (Armstrong, Rueda, Gronseth, & Mullins, 2017; Légaré et al., 2011; 
van de Bovenkamp & Trappenburg, 2009). For example, resistance from professionals to 
incorporating input from HCCs might be overcome simply by allowing HCCs to be 
involved throughout CPG development to increase their influence on decision making 
(Armstrong et al., 2017). However, some authors have pointed out that focusing on 
increasing involvement of HCCs in CPG development is not the most efficient way to 
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maximize benefits, and may actually exacerbate the challenges faced (van de Bovenkamp 
& Zuiderent‐Jerak, 2015). A better way to address challenges associated with the practice 
may be to involve HCCs in CPG development selectively, incorporating the best type of 
HCC at the right stage of CPG development, using proven methods (van de Bovenkamp 
& Zuiderent‐Jerak, 2015). Doing so requires an understanding of the available methods 
that can be used to involve HCCs in CPG development. Important details can affect the 
strengths and weakness of approaches used and the outcomes of HCC involvement, 
including which stakeholders are involved, what specific methods are used, and at what 
stage of CPG development they are employed (Légaré et al., 2011; van de Bovenkamp & 
Trappenburg, 2009; van de Bovenkamp & Zuiderent‐Jerak, 2015). 
Individual patients have been most widely discussed as important knowledge 
contributors in health care research and policy development, including in the 
development of CPGs. However, engaging patients in CPG development comes with its 
own specific challenges. For example, the unique experience of individual patients and 
constraints around how many can be practically involved in CPG development raises 
concerns about the representativeness of involved patients (Earl-Slater, 2004, p. 25; 
Légaré et al., 2011). In addition, as lay persons, patients may require training to 
effectively contribute to the CPG development process. Training of patients has been 
criticized however, as it may devalue the experiential knowledge patients are asked to 
contribute to the development of CPGs (van de Bovenkamp & Trappenburg, 2009).  
Other types of HCCs, such as family members or members of the general public, 
can also contribute to CPG development, and each group offers unique abilities to 
overcome certain challenges (Entwistle, Calnan, & Dieppe, 2008; Entwistle, Renfrew, 
Yearley, Forrester, & Lamont, 1998; Forsythe et al., 2016). In order to overcome 
concerns regarding the representativeness of patients engaged in CPG development, CPG 
development could engage patient representatives from larger patient organizations. 
Patient organizations can have separate discussions between their members on 
preferences and values for the management of specific illnesses, the results of which can 
be brought forward to guideline development groups by appointed patient representatives 
(Williamson, 1998). Patient advocates are professionals appointed to share knowledge 
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regarding patient values within guideline development groups. Patient advocates do not 
need to be members of patient organizations and may be appointed by the guideline 
development group itself. As professionals, patient advocates offer the unique ability to 
overcome certain challenges, such as the effects of perceived power imbalances between 
patients and professionals (Mallik, 1997; Roth, 2011; Williamson, 1998). Patient family 
members and informal caregivers may also be involved in CPG development and should 
be considered as separate groups, as family members and informal caregivers may have 
priorities or concerns that are different from those of patients themselves (Ahlström, 
Skärsäter, & Danielson, 2011; IOM, 2011; Roberts & Kim, 2016). Finally, members of 
the general public may wish to contribute as potential patients or as funders in publicly 
financed health care systems (Alonso-Coello et al., 2016). 
Within the categories of consumer participation, consultation, and communication 
(section 1.2.3), there is a wide variety of specific methods that can be used. Specific 
methods used for consumer consultation, for example, include focus group discussions 
among HCCs. Results of focus group discussions can be relayed back to professional 
guideline developers through a professional mediator (Tong et al., 2012). Alternatively, 
consumer consultation can involve use of surveys to gather input from HCCs (Elwyn et 
al., 2017). Consumer communication could include use of lay versions of guidelines, or 
decision aids to help patients understand their options (Gagné et al., 2017; Taddio et al., 
2013). Healthcare consumer participation is more limited in its potential varieties, as it 
requires ongoing dialogue between professionals and HCCs. Consumer participation 
might therefore be limited to involving HCCs as ongoing members of CPG development 
committees. Beyond these examples, other specific methods within each category exist, 
but these specific methods are poorly characterized. 
The creation of patient resources meant to accompany CPGs is a commonly used 
method of consumer communication. Patient resources include documents that 
accompany CPGs, meant for patient use. These can include plain-English guidelines or 
summaries, or decision aids designed to help patients weigh benefits and harms of 
potential treatments (Stacey et al., 2014; Tong et al., 2012). Although they do not offer 
opportunity for HCCs to directly influence CPG development, the utility of patient 
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resources in patient education has been verified in past studies. A review of randomized 
control trials detailing the effectiveness of patient decision aids revealed that these 
resources improved patients’ understanding of their illness (Stacey et al., 2014). Use of 
these resources also led to more accurate perceptions of risk associated with treatments, 
as indicated by scores achieved on knowledge indexes (Stacey et al., 2014). Furthermore, 
decision aids helped to reduce decisional conflict relating to feeling uniformed or unclear 
about personal values (Stacey et al., 2014). Two studies included in this review also 
demonstrated a statistically-significant difference in adherence to a chosen treatment 
option, favoring the group that was provided with a decision aid (Stacey et al., 2014).  
The process through which CPGs are created can be divided up into broad stages. 
These stages typically include formation of a guideline development group; formulation 
of key questions and outcomes for the guideline; retrieval, appraisal, and synthesis of 
research evidence; formulation of recommendations; publication and implementation; 
and finally, review and updating (Davis et al., 2007; GRADE Working Group, 2004; 
WHO, 2010; WHO, 2014). The impact of HCC involvement can vary with the stage of 
CPG development in which they are involved. For example, involving HCCs during 
formation of the guideline development group or during management of conflicts of 
interest serves to establish transparency for the development process (IOM, 2011). 
Involving HCCs during the stage of retrieval, appraisal, and synthesizing of research 
evidence may allow HCCs to have an impact on the final CPG product (Boivin et al., 
2010). However, involving HCCs specifically during evidence retrieval and appraisal 
requires greater time commitments and the need for training to understand specialized 
terminology (van de Bovenkamp & Zuiderent‐Jerak, 2015). In comparison, involving 
HCCs at the stage of formulating key questions and outcomes for the guideline allows 
HCCs to contribute without need for training (van de Bovenkamp & Zuiderent‐Jerak, 
2015). Overall, the challenges faced and the usefulness of HCC involvement may vary 
depending on the stages of development during which HCCs are asked to be involved. 
1.3 Relevance to Health Information Science 
A health information system should facilitate decision making that is based on 
sound and reliable information, through its four key functions of the generation, 
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compilation, analysis and synthesis, and communication and use of data (WHO, 2008). In 
relation, Health Information Science is concerned with knowledge translation, defined by 
the Canadian Institutes for Health Research as a dynamic and iterative process that 
includes the synthesis, dissemination, exchange, and ethically sound application of 
knowledge to improve health, provide more effective health services and products, and 
strengthen the healthcare system (Straus, Tetroe, & Graham, 2009; Western University, 
2019).  
In their overview of the process of knowledge translation, Graham and colleagues 
(2006) describe CPGs as knowledge tools, with the purpose of presenting knowledge in a 
clear, concise, and user-friendly format, influencing stakeholder decision making through 
providing explicit recommendations, and facilitating the uptake and application of 
knowledge through meeting stakeholders’ needs for information. The development of 
CPGs falls into the “knowledge synthesis” process of knowledge translation. This process 
involves utilizing explicit and reproducible methods to identify, appraise, and synthesize 
information relevant to specific questions (Graham et al., 2006). The purpose of this 
study is to characterize the methods used to involve HCCs in the development of CPGs. 
As unique knowledge holders within the healthcare system, engaging patients and other 
HCCs in the development of CPGs presents opportunity to ensure that their knowledge is 
utilized in practice and has the potential to improve the usability and outcomes of these 
tools (Armstrong et al., 2017; van de Bovenkamp & Trappenburg, 2009). Because the 
purpose of this study is to characterize a specific facet of the process of knowledge 
synthesis used to create an important knowledge tool, its area of focus is within 
knowledge translation and Health Information Science more broadly.  
1.4 Formulation of the Research Question 
This study seeks to describe how HCCs have been involved in CPG development 
in Canada. In order to limit the primary data sample to a size that would be manageable 
over the timeframe for the Master of Health Information Science program, the CPGs 
included in this study were limited to those pertaining to the management of mood and 
anxiety disorders. To provide explanation for this limitation placed on the research 
question, this section gives an outline of the relevance of mood and anxiety disorders in 
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Canada, including the role CPGs play in their management. This section also provides the 
research question for this study. 
1.4.1 Relevance of Mood and Anxiety Disorders 
Across Canada, mood and anxiety disorders are among the most common mental 
illnesses, with a combined prevalence of 11.6% in those 18 and over; even so, these 
illnesses are largely regarded as underdiagnosed (Public Health Agency of Canada 
[PHAC], 2016; McRae, O’Donnell, Loukine, Rancourt, & Pelletier, 2016; Swinson et al., 
2006). Both mood and anxiety disorders have negative impacts on overall quality of life, 
limiting a person’s ability to engage in hobbies and recreation, and interfering with their 
social and professional lives, especially when left untreated (PHAC, 2016). It is therefore 
important for those suffering from mood or anxiety disorders to be properly diagnosed 
and treated, and for the current problem of underdiagnoses to be reconciled. In addition, 
mood disorders and anxiety disorders both represent categories consisting of multiple 
illnesses with similar symptoms, but with important differences in effective treatments 
(American Psychiatric Association [APA], 2000; Scott et al., 2013). Adding to the 
complexity of their management, mood and anxiety disorders often occur together, and 
often come with other comorbid conditions, such as substance use disorders, 
schizophrenia, and attention deficit hyperactivity disorder (Bystritsky, Khalsa, Cameron, 
& Schiffman, 2013; Kessler et al., 2010).  
Clinical practice guidelines may help rectify the underdiagnoses of mood and 
anxiety disorders, by standardizing care practices used to identify and treat these illnesses 
(PHAC, 2016; Swinson et al., 2006; Woolf, Grol, Hutchinson, Eccles, & Grimshaw, 
1999). As tools meant to help healthcare providers navigate through care plans and 
provide high-quality care, CPGs are also important for aiding healthcare providers in the 
management of complex illnesses such as mood and anxiety disorders (Davis et al., 
2007). This study therefore focuses on characterizing how HCCs are involved in the 
development of CPGs for mood and anxiety disorders specifically. 
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1.4.2 Research Question 
Canadian organizations have advocated for the inclusion of HCCs in the process 
of CPG development in order to take advantage of the purported benefits (Health Council 
of Canada, 2012; Lindsay et al., 2014). However, the practice remains poorly studied in 
Canada. Characterizing the strategies used to involve HCCs in CPG development is an 
important first step in demonstrating and appraising the benefits. Given the relevance of 
mood and anxiety disorders within Canada, and the potential for CPGs to aid in their 
management, this study focuses on the strategies used to involve HCCs in the 
development of guidelines for these illnesses. The question this study seeks to answer is 
What methods are used to engage HCCs in the development of CPGs for mood and 
anxiety disorders in Canada? Specifically: 
• How are HCCs involved in CPG development? 
o At what stages of guideline development are HCCs involved?  
o What tools or strategies are used to involve HCCs in CPG 
development? 
o What groups of HCCs are involved?  
• What are the objectives or desired outcomes for engaging HCCs in CPG 
development?  
To summarize, this study’s research question is how are HCCs involved in the 
development of Canadian CPGs for mood and anxiety disorders, who is being involved, 
and why HCCs should or should not be involved in the development of these CPGs. 
Understanding the methods of HCC involvement utilized in Canada will contribute to 
indicating the quality of CPGs being produced. This study will also allow for subsequent 
analysis of the effectiveness of methods currently in use in Canada. 
1.5 Thesis Outline 
Chapter 1 has outlined a rationale for this study, important factors that should be 
included in descriptions of HCC involvement in CPG development, as well as the 
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research question this study aims to answer. Following this, Chapter 2 provides a 
description of the methodology used for this study, including a description of the 
paradigm utilized in this study. A description of the methods used for sampling and data 
analysis is provided, along with descriptions of quality considerations made for this 
study. 
 Chapter 3 provides detailed descriptions of important results gathered throughout 
this study, including descriptions of strategies for involving HCCs in CPG development, 
organized by the stage of CPG development in which they are employed. A description 
of the use of patient resources, as well as themes from interviews are also provided. 
Finally, Chapter 4 provides a summary of important findings and discusses their relation 
to existing literature. Recommendations for future research and the limitations of this 
study are also considered.  
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Chapter 2  
2 Methodology and Methods 
This chapter provides a description of the design of this study, starting with 
outlining the paradigmatic view and methodology utilized. A description of the methods 
used is also provided, including the sampling method used to gather a dataset, as well as 
the process of qualitative content analysis used. Data collection was conducted in three 
parts: collection and review of CPGs, collection and review of related material, and 
completion of interviews or questionnaires by CPG authors or methodologists. 
Qualitative content analysis was utilized to code and synthesize results into detailed 
descriptions of how HCCs have been involved in CPG development in Canada. This 
chapter also provides a description of the measures taken to ensure the quality of this 
study. Finally, a description of the ethics approval for this study is provided.  
2.1 Paradigmatic View 
This study is rooted in a constructivist paradigmatic lens, focused on uncovering 
the subjective descriptions of involving HCCs in CPG development. In order to describe 
the strategies used within Canada to involve HCCs in CPG development, this research 
involved interactions between the researcher and a dataset made up of CPGs, related 
material, and professionals involved in CPG development. The researcher recognizes that 
his own interpretations, as well as the interpretations of participants, have influenced the 
processes of data collection and analysis. This research therefore utilized a relativist view 
of ontology and a subjectivist view of epistemology, in accordance with a constructivist 
paradigm (Guba & Lincoln, 1994; Ponterotto, 2005; UK Essays, 2013). Phenomena 
described through this study have been treated as mental constructions dependent on the 
individuals who describe them (Guba & Lincoln, 1994). Information collected during this 
study is considered to have been created through the investigative process, including 
through interactions between the researcher, participants, and the dataset (Guba & 
Lincoln, 1994). While interpretation has influenced data collection, analysis and 
reporting, the researcher has strived to minimize its role, and prioritize the descriptions 
provided through dataset and research participants, versus interpretations. The researcher 
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has striven to maintain close agreement between how information is presented within the 
dataset and how it is reported.  
2.2 Methodology 
2.2.1 Qualitative Description 
Qualitative description was used in this study because it is a methodology that fits 
closely with the researcher’s views of epistemology and ontology. Use of qualitative 
description fits within a constructivist paradigm and allows the researcher to 
acknowledge the effects of subjectivity on data collection and analysis (Neergaard, 
Olesen, Andersen, & Sondergaard, 2009; Sandelowski, 2000). Use of qualitative 
description allows for minimizing the effects of this subjectivity in the form of 
interpretation. The aim of qualitative description is to provide detailed descriptions of 
phenomena in terms that are as similar as possible to those used by participants or data 
sources from which descriptions originate (Neergaard et al., 2009). Even so, proponents 
of qualitative description do not assert that “pure description”, in line with a positivist 
view of ontology and epistemology, is possible (Neergaard et al., 2009; Sandelowski, 
2000). In contrast, according to Sandelowski (2000), researchers utilizing qualitative 
description should recognize that descriptions of a target phenomenon will always entail 
some level of interpretation. Sandelowski (2000) recognizes that “there is no pure 
looking with a naked, innocent eye”, and that descriptions will always depend on the 
perceptions and sensibilities of the describer. Therefore, Sandelowski’s (2000) 
description of qualitative description falls within a constructivist view of epistemology 
(Guba & Lincoln, 1994; Pearce, 1971). In this study, choices have been made regarding 
what data to present from large datasets, demonstrating the impact of researcher 
subjectivity on what is presented as findings. 
Qualitative description borrows tenets from naturalistic inquiry to study 
phenomena in their natural state (Neergaard et al., 2009; Sandelowski, 2000). In 
alignment with naturalistic inquiry, variables are not manipulated, and there is no 
commitment to pre-existing theories, in order to allow data to be analyzed in a form it 
would be likely to appear if it were not under study (Lincoln & Guba, 1985; 
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Sandelowski, 2000). However, researchers are still allowed to create linkages between 
presentation of a current dataset and previous research (Neergaard et al., 2009). For this 
research project, this allows descriptions resulting from the current dataset to be guided 
by previously completed work. A literature review was therefore completed for this study 
to determine the factors that are likely to affect the outcomes of HCC involvement in 
CPG development. This literature review has been used to guide the aspects of this 
practice that are presented as findings for the current study. 
2.2.2 Role of the Researcher 
While I have sought to minimize the influence of interpretation on findings 
presented in this study, in line with both the constructivist paradigmatic view and 
qualitative description methodology utilized, I acknowledge that my own experiences and 
decisions influence this study.  
I grew up in a small town in Northern Ontario, with parents who both work in the 
healthcare sector. As clinicians, my parents would often have stories of conflict with 
patients, who would request unnecessary or potentially harmful treatments, or who would 
become non-compliant with treatments likely to be effective. I became aware of the role 
of patients in their own healthcare through these discussions with my parents. I developed 
an understanding of the need for patients’ involvement in their own healthcare, such that 
it meets their needs for education, and the integration of their own personal values. My 
interest in exploring and developing strategies for including patients in their healthcare 
for their own benefit has been a result of my childhood experiences with my parents’ own 
careers. 
From my experience arises a potential bias in this research. I believe that patient 
involvement in healthcare research, development, design, and delivery is a practice that 
should be utilized in order to facilitate agreement between patients, their care providers, 
and their care plans. This has affected my decision to focus on the benefits of HCC 
involvement in CPG development throughout this study. It may have also influenced the 
framing of questions used in interviews, as well as my own interpretation of data 
gathered throughout this study. Finally, it may have influenced how this information was 
framed in its reporting and discussion within this thesis. 
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My interpretations of the dataset utilized in this study, and the resulting findings 
that are presented, are influenced by my own review of the existing research literature. 
Through review of existing research, I have formulated my research question based on 
what others have previously described to be important factors in involving patients and 
other lay members of the public in the development of CPGs. Information from previous 
research has also influenced the processes of extracting important information from my 
data sources and coding this information. Review of previous research has allowed me to 
determine that important factors to consider are the specific groups involved, such as 
patients or family members, the stage of CPG development these stakeholders are 
involved in, and the specific methods used. I have striven to allow answers to my 
research question to arise directly from my data sources in the form of codes, but my 
decisions regarding how to code collected information have been influenced by 
descriptions of similar information provided in previous studies. 
2.3 Methods 
2.3.1 Design 
This study has been conducted in three parts, consisting of collection and review 
of CPG documents, collection and review of related material, and correspondence with 
CPG authors or methodologists through interviews or questionnaires. Similar methods 
have been used in previous studies in order to describe involvement of patients in CPG 
development outside of Canada (Armstrong & Bloom, 2017; Légaré et al., 2011). 
Armstrong & Bloom (2017) identified information contained within webpages and CPG 
development manuals to identify organizations that involve patients in their CPG 
development processes. For organizations where information could not be gathered from 
these sources, these authors utilized information contained within the most recently 
published CPG from these organizations to identify information regarding their 
methodology (Armstrong & Bloom, 2017). Légaré and colleagues (2011) sought to 
describe key components of existing patient and public involvement programs in CPG 
development. To achieve this, Légaré and colleagues collected descriptions of patient and 
public involvement programs from qualitative and quantitative research articles, as well 
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as from documents describing these programs that were produced by national- or 
government-supported or non-profit organizations that produce CPGs.  
In this study, a sample of CPGs pertaining to the management of mood and 
anxiety disorders was collected using searches of PubMed and the CMA CPG InfoBase. 
Secondly, organizations involved in the development of each guideline were identified 
using information contained within each CPG. Google searches were used to locate 
websites corresponding to each organization. Relevant websites were searched for 
sections, passages, or documents that describe the CPG development process adhered to 
by the respective organization. Finally, authors or organizations listed as a 
correspondence contact for each CPG were contacted for the purpose of conducting an 
interview or alternatively completing a questionnaire. Four interviews and two 
questionnaires were completed for this study. A full description of the sampling method 
used in this study is provided through section 2.3.2 and section 2.3.3.  
Inductive qualitative content analysis was used to code information contained 
within the data sample for this study and create final categories to be presented as results. 
Information contained within CPG documents and web-based material was used to 
identify how HCCs have been involved in CPG development, including what groups of 
HCCs have been involved, what strategies have been used, when they are involved, and 
for what purpose. Interviews and questionnaires were used to gather information 
pertaining to the strategies used to involve HCCs in CPG development. Interviews and 
questionnaires were also used to gather information pertaining to professional 
perspectives regarding the value of HCC involvement in CPG development and why this 
practice is used or avoided. A full description of the analytic approach used in this study 
is available in section 2.3.4 and section 2.3.5. 
2.3.2 Criterion Sampling and Total Population Sampling 
Purposeful sampling is a sampling method that is used commonly within 
qualitative descriptive studies and that is likely to compile a dataset containing high-
quality information (Neergaard et al., 2009). Purposeful sampling involves utilizing 
existing information in the field of study to help identify information-rich cases (Suri, 
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2011). As specific types of purposeful sampling, this study utilized both criterion 
sampling and total population sampling (Lund Research, 2012; Suri, 2011).  
Criterion sampling involves seeking a sample that meets a pre-determined set of 
inclusion criteria (Coyne, 1997; Suri, 2011). In line with the method of criterion 
sampling, this study based its sampling criteria on previously completed studies 
(Armstrong & Bloom, 2017; Légaré et al., 2011; Suri, 2011). This study utilized 
characteristics of CPGs outlined by the IOM (2011) and by other previous publications to 
define its sampling population (Alonso-Coello et al., 2011; Shekelle et al., 2001). Further 
inclusion criteria resulting from the research aim provided strict limitations on the CPGs 
considered in this study. Criterion sampling was used to define the population of CPGs 
that this study used as the basis of analysis.  
Use of criterion sampling also allowed the researcher to seek out further 
information directly related to CPG documents that fit inclusion criteria from related 
documents, web-based material, and from interviews and questionnaires conducted with 
professionals involved in CPG development. Using CPGs and related material to define a 
dataset has been used successfully in similar studies (Armstrong & Bloom, 2017). In her 
description of purposeful sampling, Coyne (1997) outlines that this type of sampling can 
be planned at the beginning of a study based on existing knowledge of where high-quality 
information is likely to be found. In line with this, documents that describe CPG 
development procedures included in this study were sought out only before data analysis 
began. Professionals from organizations that developed CPGs included in this study were 
also invited to participate in interviews or questionnaires. Interviews and questionnaires 
were completed before data analysis began. Sampling was not done simultaneously with 
data analysis and was not done to contribute to the creation of a theory emerging from 
data, as in theoretical sampling (Coyne, 1997). To summarize, criterion sampling, a 
specific type of purposeful sampling, was utilized in this study because it allowed for the 
collection of data sources likely to provide important information, but did not require 
sampling to continue throughout data analysis in order to contribute to any emerging 
theories (Coyne, 1997; Suri, 2011).  
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Total population sampling involves gathering information from the entire 
population of units with particular characteristics (Etikan, Musa, & Alkassim, 2016; Lund 
Research, 2012). This study utilized CPGs that fell into a predetermined set of criteria as 
its sampling population and used each of these as starting points to gather a broader 
dataset that related directly to these documents. Because every CPG that adhered to 
inclusion criteria were analyzed in this study, total population sampling was also used, in 
addition to criterion sampling (Etikan et al., 2016; Lund Research, 2012). The number of 
CPGs that met inclusion criteria was relatively small, making total population sampling a 
reasonable choice for this study (Etikan et al., 2016). Total population sampling was also 
used in gathering related data sources for CPGs that met inclusion criteria. Web-based 
material describing the development of CPGs was collected for each CPG. In addition, 
recruitment materials were sent to one professional or one organization involved in the 
development of each CPG included in this study. Further details on the sampling method 
used in this study are provided in section 2.3.3. 
2.3.3 Sampling and Recruitment Method 
For this study, clinical practice guidelines were defined as review documents that 
contain recommendations based on systematic review of available evidence and/or expert 
consensus, meant to inform primary care physicians, medical specialists, or allied health 
clinicians in the diagnosis, assessment, and treatment of illness (American Academy of 
Family Physicians, 2017; Davis et al., 2007; IOM, 2011). The primary data sample for 
this study consisted of CPGs written in Canada to aid in the management of mood and 
anxiety disorders. Limiting the data sample to CPGs pertaining to the management of 
mood and anxiety disorders was done primarily as a means to ensure that the data sample 
remained small enough to analyze and describe within the timeframe of the Master of 
Health Information Science program for which this study has been completed. Section 
1.4.1 provides a rationale for limiting the primary data sample to CPGs pertaining to the 
management of mood and anxiety disorders. Previous studies have demonstrated that 
many CPGs require updating within six years of publication, and most organizations that 
develop CPGs review and update these publications at least every five years (Alonso-
Coello et al., 2011; Canadian Medical Association [CMA], 2018; Shekelle et al., 2001). 
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Consistent with this, to be included in this study, CPGs must have been published or most 
recently updated after January of 2013, five years prior to the initiation of this study. 
Inclusion criteria for the primary data sample for this study were: 1) documents 
must meet the definition of CPG previously given, 2) CPGs and included 
recommendations must pertain primarily to the management of mood or anxiety 
disorders, as they are defined by the DSM-IV or DSM-V, 3) CPGs must be 
commissioned or developed by, or done so in conjunction with, a Canadian organization, 
4) CPGs must be available and free for public use and 5) CPGs must be the most recent 
version of the respective guideline. Clinical practice guidelines published as a series or as 
multiple documents were considered as one guideline, but all relevant parts were 
analyzed for data extraction. 
Collection of a primary data sample was completed using searches of databases 
likely to contain CPGs. As a known index for up-to-date CPGs, the Canadian Medical 
Association (CMA) CPG Infobase was first searched for relevant guidelines. Each result 
from the CMA CPG InfoBase were subject to a review of titles, abstracts, and author 
information to identify results that met inclusion criteria for this study. The CMA CPG 
InfoBase revealed 23 results relevant for use in this study. PubMed was also searched for 
relevant guidelines. Search terms used within PubMed were not designed to identify an 
exhaustive list of CPGs fitting the aforementioned criteria, but rather were limited to a 
short list of terms in order to ensure CPGs analyzed in this study remained clinically 
relevant (Appendix A). Results were limited to those published between January 2013 
and July 2018 consistent with the inclusion criteria. Search results from PubMed were 
also subject to a brief review of titles, abstracts, and author information to isolate results 
that were relevant for this study. Results from the CMA CPG Infobase and PubMed were 
combined using Zotero, a resource management program, and duplicate results were 
identified and removed. Remaining results deemed to be relevant were subject to a full-
text review to ensure adherence to inclusion criteria for this study. Finally, results 
belonging to CPGs published as a series were combined to be considered as complete 
CPGs. A total of twelve complete CPGs were found to be relevant for inclusion 
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following full review (Appendix B). The process of collecting the primary data sample 
for this study was completed in July of 2018. 
Following identification of the initial data sample, descriptions of how these 
documents were developed were sought. First, any documents referenced by each CPG 
that contained descriptions of development procedures were identified and collected. 
Organizations credited with or claiming responsibility for the development of or 
production of each guideline were also identified through review of author and publishing 
information contained within each CPG. Organizations that were credited only with 
funding or endorsement of the CPG, or the organizations affiliated with individual 
authors were not considered. Additionally, organizations credited only for creating a 
literature review protocol, participating in the review and comment, or publishing the 
CPG in question were also not considered.  
Following identification of relevant organizations, Google was used to search for 
information corresponding to each of these organizations. The title of each organization 
that develops CPGs identified as relevant for this study was used as a search term. These 
searches were meant to identify the most up-to-date webpage corresponding to each 
organization responsible for the development of a CPG analyzed in this study. For each 
search term used, the first two pages of results were searched through to identify websites 
or documents belonging to these organizations. Relevant websites were those directly 
corresponding to the organizations that produced a CPG being considered, or a website 
for a parent organization. Each website was searched for descriptions of how the 
respective organization develops CPGs. Webpages were reviewed in full for descriptions 
of HCC involvement in their programs. Only the webpages directly related to the 
organizations being considered were reviewed in cases where, for example, these 
organizations were subsidiaries of larger organizations. Passages describing CPG 
development procedures were copied and saved into a word document, along with the 
corresponding URL. Documents made available with each website deemed likely to 
contain descriptions of CPG development procedures were identified and collected. 
These included, but were not limited to, annual reports, procedure manuals, policy 
documents, and program overviews. Financial reports were not collected for review. 
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Webpages and documents were not excluded from review or analysis based on their 
publication date. Collection of information from web-based material was completed from 
October of 2018 through to April of 2019. 
Professionals involved in the development of CPGs analyzed in this study were 
also interviewed or invited to complete a questionnaire. Ethics approval for this study 
was granted by the Western University Non-Medical Research Ethics Board (ID# 
112558). For this study, professionals were considered to be individuals with formal 
training or education within healthcare and health services and policy design, excluding 
patient advocates. Previous research has used interviews with professionals involved in 
CPG development to gather information on their experiences with HCC involvement in 
CPG development, and the perceived value of this involvement, although it focused on 
CPGs developed in the Netherlands (van de Bovenkamp & Zuiderent-Jerak, 2015). In 
this study, interviews and questionnaires were primarily used to gain a deeper 
understanding of professionals’ views regarding the involvement of HCCs in CPG 
development, and why HCCs are or are not involved in CPG development. This decision 
was made a priori, after considering that professionals would have expertise in CPG 
development and insight into the potential value of involving HCCs in this process. 
Interviews and questionnaires were also used to verify and add to data collected through 
an initial review of CPGs and related web-based materials. 
Total population sampling was utilized to recruit authors or other professionals 
involved in the development of CPGs. CPG authors were chosen as the target population 
for recruitment because 1) they represented a group of professionals whose involvement 
in the development of the respective CPG could be reliably verified and 2) contact 
information for the first author of the CPGs included in this study were often made 
available in the CPG itself. For those CPGs that provided it, contact information was 
collected for the corresponding author. For CPGs that provided an organizational email 
explicitly as a correspondence contact, this email was collected, in substitution of an 
author email.  
If contact information for a corresponding author or for an overseeing 
organization was not made available within the CPG document itself, the first author’s 
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institutional affiliations were collected from the CPG. A Google search was used to 
identify the webpage corresponding to the first listed affiliate institution. Search terms 
used were composed of the author’s first and last name, in combination with the 
institution’s name. The author’s e-mail address and phone number were collected from 
the first webpage that provided this information, provided it was made publicly available. 
This information was preferentially collected from webpages belonging to the first 
identified affiliate institution. 
The first author or organization for each CPG under review, for which contact 
information could be collected, was contacted by email in order to request they 
participate in an interview or complete a questionnaire for this study. In cases where no 
response was received within two weeks, a reminder email was sent. If, after one week 
from sending the reminder email, the first contacted author or organization had not 
responded, the author or organization was called. If these attempts to reach the first 
author or organization were unsuccessful, the next author or organization for which 
contact information was publicly available was contacted by email once. Contact 
information for the second author or organization was collected using the same procedure 
described previously. Recruitment emails and telephone calls followed a recruitment-
style script and indicated how the author’s contact information was obtained, who was 
conducting the study, and what the study required from participants (Appendix C and 
Appendix D). Recruitment materials also presented opportunity for the contacted author 
or organization to forward the recruitment script to individuals who would be better able 
to answer questions regarding the involvement of HCCs in the development of the 
respective CPG. A letter of information and consent was provided as an attachment to 
recruitment emails (Appendix E). Recruitment materials were sent to potential 
participants from November of 2018 to January of 2019. 
Although listed authors served as the initial point of contact for recruitment for 
this study, they were not the only professionals invited to participate in interviews. The 
email recruitment script did not indicate that CPG authors were the desired population, 
and these recruitment emails contained directions to forward them to the professional 
who would be the most capable of addressing the study’s subject matter (Appendix C). 
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Professionals involved in this study therefore varied in their area of expertise and in their 
level of involvement in the development of each CPG analyzed. The decision to allow for 
variance in the role in CPG development and area of expertise within professionals 
participating in interviews was made a priori, in order to increase the likelihood of 
response by potential participants. The roles of each professional who participated in this 
interview are described later in this section. 
Through communication via email or phone calls, participants who had responded 
to recruitment materials were presented with the opportunity to schedule an interview at a 
time convenient for them. Interviews were conducted via telephone, to ensure geographic 
location did not hinder the researcher’s ability to reach participants. Interviews followed 
a semi-structured design and consisted of open-ended questions regarding why HCCs 
were or were not involved in the development of the respective CPG, and how this 
occurred (Appendix F). Participants were asked to comment on or clarify information 
collected through the review of CPGs or related material in cases where information was 
found describing the involvement of HCCs in CPG development from these sources. 
Participants were also asked to comment on the value of HCC involvement in CPG 
development, as well as any challenges or facilitators for the process, when appropriate. 
Interviews took twenty to thirty minutes to complete.  
Interviews were audio-recorded using the Apple Voice Memos application, and 
audio recordings were transcribed verbatim by the researcher. To ensure accuracy of 
transcription, and to add to the rigour of this study, completed transcripts were reviewed 
at least twice while listening to the corresponding interview recording (Milne & Oberle, 
2005). Completed transcripts were handed back to participants to allow them to check for 
accuracy and provide further comment, again to add to the rigour of this study (Milne & 
Oberle, 2005). The concept of rigour as it applies to this study is further discussed in 
section 2.4.1. The process of conducting interviews, transcribing audio-recordings, and 
reviewing the transcripts was completed from December of 2018 to March of 2019. 
Related data sources were reviewed, but not coded, prior to conducting the corresponding 
interview, to give the researcher the opportunity to ask for clarification on any relevant 
information if needed. 
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Through recruitment materials, participants were also provided the option to 
complete a questionnaire if they were unwilling or unable to schedule a telephone 
interview. Upon their request, participants were provided a secure link to a questionnaire 
created using the Qualtrics tool. Participants were also provided a unique six-digit code to 
be entered into the survey to identify their responses. A list of these codes and the 
corresponding participant names was kept by the researcher as a Microsoft Word file on a 
password protected and encrypted flash drive. Open-ended questions were used to gather 
relevant information equivalent to that gathered through interviews (Appendix G). These 
questions were also suited to collect data on how HCCs were involved in CPG 
development, and why HCCs were or were not involved in this process.  
In total, six participants contributed information for this study through 
participation in interviews or questionnaires. Two individuals were the primary authors of 
the respective CPG analyzed for this study and both of these participants completed 
questionnaires. Four individuals participated in interviews, and each of these individuals 
held positions in either quality improvement or research coordination at their respective 
organizations.  
Finally, in two cases, participants forwarded the researcher additional materials 
describing the development of the respective CPG, or material describing how HCCs 
were involved in this process. Materials received this way included a peer-reviewed 
journal article as well as a webpage corresponding to an additional organization that had 
created a patient resource for the respective CPG. The peer-reviewed journal article was 
collected for analysis, and the webpage was reviewed in an identical fashion to those 
webpages identified through Google searches, to collect information describing how 
HCCs were involved in the development of the respective CPG. 
2.3.4 Qualitative Content Analysis 
Qualitative content analysis is a method that is used to systematically describe or 
interpret information (Graneheim & Lundman, 2004). Qualitative content analysis 
involves combining codes into categories that are titled based on language used directly 
in the dataset (Elo & Kyngäs, 2008). Abstraction of data is allowed to stop at this point, 
and the researcher can report these categories as minimally theorized descriptions of the 
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dataset (Erlingsson & Brysiewicz, 2017; Vaismoradi et al., 2013). Use of qualitative 
content analysis therefore helps to minimize effects of the researcher’s interpretations and 
allow descriptions to remain in close agreement with the dataset. Qualitative content 
analysis still allows the researcher to view description and interpretation as existing on a 
continuum, with description always entailing some amount of interpretation 
(Sandelowski, 2000). Use of this method therefore allows the researcher to view data 
creation and analysis as a constructive act and encourages the researcher to recognize 
their biases and preconceptions during analysis (Sandelowski, 2010; Vaismoradi et al., 
2013). Because the researcher viewed research data and results arising from its analysis 
as constructed through interactions between the researcher, the data, and participants, 
qualitative content analysis is a suitable choice for data analysis in this research. 
For use in this study, a meaning unit was defined as a verbatim passage taken 
from the dataset that described a phenomenon of interest (Erlingsson & Brysiewics, 
2017). Furthermore, a meaning unit was any sentence or paragraph that described how 
HCCs are involved in CPG development. Codes were defined as labels that described 
what a particular meaning unit was about, and that were usually one or two words long 
(Erlingsson & Brysiewicz, 2017). To describe the dataset in detail, multiple codes may 
have been applied to any individual meaning unit. A category was formed by combining 
codes that were related in their content (Erlingsson & Brysiewicz, 2017). Categories were 
used to address the question of who is being involved in CPG development, how this is 
happening, and why. Creation of themes requires a higher level of abstraction. Themes 
express an underlying meaning, or a connection between categories that has been 
interpreted by the researcher (Erlingsson & Brysiewicz, 2017). This study used themes to 
express ideas that emerged from interviews only, that regard the motivations for 
involving HCCs in CPG development, and the increasing efforts to involve HCCs in CPG 
development. Themes have not been used to describe the actual strategies that have been 
used to involve HCCs in CPG development. 
Inductive content analysis is an appropriate choice for data coding in research that 
aims to minimize use of existing theory while still providing detailed descriptions of a 
target phenomenon (Neergaard et al., 2009). In inductive qualitative content analysis, 
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existing theory should not guide creation of codes. Instead, codes should originate from 
data being analyzed, and summarize important concepts (Erlingsson & Brysiewicz, 
2017). Codes should be combined into categories, to provide comprehensive descriptions 
of important information. In order to provide a detailed description that remains in close 
agreement with the dataset, each unique code should be integrated into final categories 
(Granheim & Lundman, 2003). In addition, codes should not be assigned a relative level 
of relevance based on their frequency of occurrence (Erlingson & Brysiewicz, 2017).   
2.3.5 Analytic Approach 
Qualitative content analysis was used to analyze information from CPGs, related 
material, and interviews (Neergaard et al., 2009; Sandelowski, 2000). Individual CPGs 
were considered the primary unit of analysis for this study. Data pertaining to an 
individual CPG, including the CPG itself, related materials and interview transcripts, 
were coded and categorized together. As an important first step in data analysis, all 
information pertaining to an individual CPG was reviewed before coding was conducted 
for this CPG. This allowed the researcher to become familiar with the dataset before 
codes were applied (Erlingsson & Brysiewicz, 2017). Inductive content analysis was then 
applied to analyze individual CPGs, their related materials, and interview or 
questionnaire information if available, to provide descriptions of who was involved in 
this CPG’s development, as well as how and why they were involved. Inductive content 
analysis was utilized to code data because the researcher sought to minimize use of 
existing theory while still providing detailed descriptions of HCC involvement in CPG 
development.  
Meaning units were pulled from each data source, and codes were subsequently 
applied to those meaning units. Important concepts pulled from the dataset included 
descriptions of what groups HCCs belonged to, what stage of development these 
individuals were involved in, the direction of information flow between professionals and 
HCCs, and why these individuals were being involved.  
In accordance with use of inductive qualitative content analysis, existing theory 
did not dictate creation of predetermined codes. Instead, codes were generated from data 
being analyzed, and were used to summarize important concepts (Erlingsson & 
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Brysiewicz, 2017). For each individual CPG and its related materials, codes were 
combined into categories, to provide comprehensive descriptions of information deemed 
important for answering the research question. In order to provide detailed descriptions 
that remained in close agreement with the dataset, each code was integrated into final 
categories (Granheim & Lundman, 2003). Categories served as the final level of 
reporting for describing the strategies that have been used to involve HCCs in CPG 
development, to avoid further reliance on interpretation (Elo & Kyngäs, 2008; Erlingsson 
& Brysiewicz, 2017).  
As analysis progressed for an individual CPG, codes and categories were 
compared with those applied in previously analyzed CPGs to ensure consistent 
application of similar descriptors (Erlingsson & Brysiewicz, 2017). However, codes from 
separate CPGs and their related materials were not combined to finalize codes and 
categories to be applied across the data set. This was done to allow for creation of 
descriptions that remained closely in line with information contained within the initial 
dataset (Neergaard et al., 2009).  
In addition to analyzing materials related to individual CPGs as a unit, interviews 
were analyzed independently from other data sources. Interviews contained important 
information regarding the professionals’ perceptions of the value of HCC involvement, 
and the efforts that have been made to utilize the practice. This information did not 
pertain to individual strategies of HCC involvement in CPG development. To convey this 
information, the appropriate categories arising from interviews only were combined to 
form themes. The researcher strived to ensure that themes were used only to connect 
related categories and not to convey latent or underlying content, to minimize the effects 
of the researcher’s interpretation (Erlingsson & Brysiewicz, 2017).  
Throughout data analysis, reflexive notes were taken to document decisions made 
regarding what information was incorporated into codes, categories, and themes (section 
2.4.2). The research advisory committee was involved in confirming decisions regarding 
what information to include in codes, categories, themes, and the final presentation of 
results. The researcher has also utilized reflexivity to document how his knowledge of 
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existing theory may have influenced the descriptions of HCC involvement in CPG 
development that were produced throughout this study, as described in section 2.4.2.  
2.4 Quality Considerations 
In line with the use of a qualitative descriptive methodology and the constructivist 
paradigm underpinning this study, the researcher has considered data collected as co-
constructed by himself, interview participants, the authors of analyzed documents, and 
the research advisory committee members. The researcher realizes that data labelled as 
important, and interpretations of this data, may vary between researchers. However, the 
researcher has striven to ensure that descriptions of HCC involvement in CPG 
development resulting from this study follow participant data directly, by following the 
description of qualitative description given by Sandelowski (2000; 2010). This effect is 
enhanced through using categories of information as the final level of abstraction of data 
to describe how HCCs have been involved in CPG development, rather than extending 
interpretation to create themes (Erlignsson & Brysiewicz, 2017). In considering how 
quality would be achieved throughout this study, Tracy’s (2010) “big tent” criteria were 
each considered. Because the research has aimed to minimize the effects of interpretation, 
important quality considerations for this study include rigour and credibility (section 
2.4.1), and sincerity (section 2.4.2; Milne & Oberle, 2005; Neergaard et al., 2009; Tracy, 
2010). Furthermore, Tracy’s (2010) criteria of rigour, credibility, and sincerity have each 
been described as important in the use of qualitative description, or in the use of a 
constructivist paradigm (Neergaard et al., 2009; Salkind, 2010).  
2.4.1 Rigour and Credibility 
For this study, rigour has been defined as the thoroughness, richness and care put 
into data collection, analysis, and reporting (Tracy, 2010). Within a constructivist 
paradigm, researchers reject the notion of objectivity, and therefore accept themselves, 
including their preconceptions and sensibilities, as part of the research process and its 
results (Salkind, 2010). Within a constructivist paradigm, interactions between researcher 
and participants, or even the researcher and the dataset, must be described as a crucial 
part of the research project (Salkind, 2010). Rigour in qualitative description therefore 
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involves detailed description not only of the dataset, but also of how the research process 
proceeded and how results were affected by interactions between the researcher, their 
existing ideas, the dataset, and research participants. 
Credible research is that which “readers feel is trustworthy enough to act on and 
make decisions in line with” (Tracy, 2010). Achieving credibility involves providing 
thick description of methods and results and working towards crystallization. Thick 
description involves reporting data and conclusions in abundant detail (Tracy, 2010). 
Similar to rigour, thick description is necessary to provide an adequate description of 
HCC involvement in CPG development and to provide a solid basis for conclusions made 
by the researcher. Crystallization in qualitative research refers to the idea that if two or 
more sources or types of information can converge on the same conclusion, then the 
conclusion is more valid (Tracy, 2010). The term “crystallization” is used instead of 
“triangulation”, in order to acknowledge that results remain partial constructions of an 
issue, even if they are collected from multiple data sources or types of data, or using 
multiple theoretical frameworks (Tracy, 2010). The use of crystallization as a quality 
criterion therefore remains in close agreement with the constructivist paradigm utilized 
throughout this study. Achieving crystallization requires researchers to gather 
information from multiple data sources to provide an in-depth, but still subjective, 
understanding of an issue (Tracy, 2010). This concept has been applied in the current 
research through collection of information through CPGs, related documents, and 
interviews in order to gather detailed descriptions of HCC involvement in CPG 
development. The author realizes that data collected in this manner do not converge on a 
single “truth” of what strategies are used, but instead result in a more in-depth description 
constructed through interactions between the researcher, the dataset, and participants. 
The rigour of this research project has been enhanced through the collection of 
information from multiple data sources. Specifically, information describing how HCCs 
were involved in the development of each CPG under review has been pulled from the 
CPG documents themselves, related materials found online originating from 
organizations responsible for their development, as well as from interviews or 
questionnaires completed with professionals from these organizations. Clinical practice 
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guidelines and related information taken from the related organizations have been used as 
data sources in similar studies (Armstrong & Bloom, 2017; Légaré, 2011). These 
studies were able to provide in-depth descriptions of strategies used to involve HCCs in 
CPG development outside of Canada. The use of multiple data sources in this study has 
contributed to the detail of the descriptions of strategies used to involve HCCs in CPG 
development. Use of participant interviews has added to the comprehensiveness of data 
sources when compared to those used in previous studies, contributing to the rigour of the 
current study. 
The researcher has identified aspects of HCC involvement in CPG development 
likely to influence the usefulness of these strategies, and the challenges encountered. An 
awareness of existing theory and descriptions given in the literature has allowed the 
researcher to detect nuance in the dataset and make appropriate decisions regarding what 
is important for addressing the aims of this study (Tracy, 2010). While utilizing existing 
theory is useful for detecting nuance in the dataset, in studies utilizing qualitative 
description, it is important to allow codes applied to the data to originate from the data 
itself (Milne & Oberle, 2005). To reduce the influence of the use of existing theory on 
data analysis, and therefore keep the process of data analysis commensurate with a 
qualitative descriptive methodology, the researcher has documented his preconceptions 
and biases resulting from literature review within reflexive notes as appropriate. A 
summary of these is available in section 2.2.2. The researcher’s decisions regarding what 
was considered important information for coding, and how to code and categorize this 
information have also been documented (Tracy, 2010). These decisions have been 
focused on ensuring that codes originate from the data sources analyzed in this study. 
Decisions made throughout the completion of this research, as well as the corresponding 
reflexive notes, have been shared with the research advisory committee for this project. 
In addition to adding to the rigour of this study, the use of multiple data sources 
for each guideline under review provides a useful tool for crystallization (Tracy, 2010). 
As previously mentioned, information from online sources has been reviewed, and 
interviews with professionals involved in CPG development have been conducted, in 
addition to the initial review of CPGs themselves. Throughout the analysis of individual 
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CPGs and their related data sources, codes emerging from the dataset were critically 
reviewed to ensure similar codes were consistently applied when appropriate, and new 
codes were created when required (Milne & Oberle, 2005). Furthermore, as data analysis 
progressed, the researcher returned to previously analyzed CPGs and their related data 
sources, in order to ensure consistent application of codes and categories between CPGs 
(Elo et al., 2014). Comparison of coding and categorization between individual CPGs 
was not done to influence the content of codes, but only to ensure that similar codes and 
categories were applied consistently. Analysis of different data sources has allowed the 
researcher to ensure that information analyzed in this study was understood more deeply 
and interpreted consistently, so that congruent and in-depth descriptions of perceptions of 
the dataset could be given (Tracy, 2010). Use of multiple sources of information has 
therefore ensured that this research achieved crystallization and credibility, while 
maintaining its agreement with a constructivist paradigm (Neergaard et al., 2009; Tracy, 
2010).  
2.4.2 Sincerity and the Reflexive Process 
Sincerity involves transparency, or honesty about the research process (Tracy, 
2010). Achieving transparency involves providing clear documentation of decisions made 
and activities conducted throughout the research process (Tracy, 2010). The transparency 
of this study has been achieved through providing details on the proceedings of this study 
and the methods used, including how information was coded, and the level of detail 
included in transcriptions, for example (provided in section 2.3.3 and section 2.3.5; 
Tracy, 2010). The limitations of this study and a personal reflection are also given in 
section 4.2 and section 4.4 respectively, to outline the challenges encountered in this 
study (Tracy, 2010).  
Sincerity also involves self-reflexivity, or the process of promoting honesty and 
authenticity with one’s self, one’s research and one’s audience through self-assessment of 
biases and motivations (Tracy, 2010). Use of reflexivity allows the personal experiences 
of researchers to be documented and analyzed for their potential effects on data analysis 
(Salkind, 2010). Because the experiences and interpretations of the researcher are 
considered an essential component of the data within a constructivist paradigm, the use of 
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reflexivity is required within studies that utilize this paradigm (Salkind, 2010). Within 
qualitative description, reflexivity can also help the researcher to reduce the effects of 
their perceptions, inclinations, and sensibilities on data analysis (Neergard et al., 2009). 
The use of reflexivity to document potential sources of bias or influence, what measures 
were taken to reduce the effects of these influences, as well as how decisions were made, 
are therefore important in this study.  
As outlined previously, the researcher has documented his preconceptions and 
potential sources of bias and has used self-reflexivity to describe how his knowledge of 
existing theory surrounding HCC involvement in CPG development may have influenced 
this study and its results. A summary of these is provided in section 2.2.2. Reflexive 
notes have also been taken throughout the research process in order to document details 
of interactions between the researcher, the dataset, and interview participants, and their 
possible influence on data analysis. The researcher has kept detailed notes regarding what 
was considered important to be included in the coding and categorization of analyzed 
data. Decisions regarding how to code information that was considered important were 
also rationalized, and these rationalizations were recorded. The researcher’s reflexive 
notes regarding his preconceptions and biases, and regarding the decision making done 
during data analysis have been shared with the research committee members involved to 
ensure the credibility of this study (Tracy, 2010). A summary of reflexive notes taken 
throughout the research process is provided in Appendix H. 
The role of the research participants in this study has also been considered 
through reflexivity. Participants recruited for involvement in this research have played a 
significant role in the development of the CPGs analyzed in this study or have been 
identified as the individual best suited to provide valuable information for this study by 
their respective organization, following review of recruitment materials. Although the 
population of potential participants has been limited by the inclusion criteria applied to 
the initial sample of CPGs gathered for this study, the role each participant has played in 
the development of the respective guideline has varied. To compensate for this, the role 
of each participant in the development of the respective guideline has been documented 
and considered during data analysis and communicated in this thesis (section 2.3.3).  
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2.5 Ethics 
The Western University Non-Medical Research Ethics Board approved this study 
(ID# 112558; Appendix I). A letter of information and consent was provided to 
participants through recruitment emails (Appendix E; Western University, 2017b). In 
cases where interviews were conducted, participants were asked to confirm that they had 
reviewed the letter of consent and provide verbal consent for participation after having 
reviewed the letter of information. The researcher made note of having asked the 
participant these questions and of the participant’s answers. For each interview 
conducted, verbal consent to participate was audio-recorded. Interview audio-recordings 
were transferred to an encrypted and password protected flash drive (Western University, 
2017a). Participants were presented with the opportunity to forgo audio recording of 
responses to interview questions. In cases where questionnaires were completed, return of 
a completed questionnaire was assumed to signify consent to participate in this study and 
this was made clear in the letter of information provided to participants. Participants who 
completed a questionnaire for this study were provided with a random six-digit code to be 
attached to their completed questionnaire. A list of these codes and the names of the 
corresponding participant was kept by the researcher on a Microsoft Word file on a 
password protected and encrypted flash drive. 
Names of participants were replaced by a pseudonym for the purpose of data 
analysis and reporting. Any other identifiable information included in the data collected 
during correspondence with participants, such as titles of CPG documents or professional 
organizations, was removed from the data set. All information collected throughout this 
study was kept on an encrypted and password protected flash drive. This flash drive will 
be kept for a period of seven years following the researcher’s completion of the Master of 
Health Information Science program for which this study was conducted. After this 
period, the flash drive used to store this information will be sanitized (Western 
University, 2017a). 
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Chapter 3  
3 Results 
The results for this study primarily focus on the strategies that have been or that 
are used to involve HCCs in CPG development in Canada. These results are divided into 
four different parts, corresponding to the four parts of this study’s research question:  
1) what stages of clinical practice guideline (CPG) development are healthcare 
consumers (HCCs) involved in; 
2) what tools or strategies are used to involve HCCs in CPG development; 
3) what groups of HCCs are involved; 
4) and what are the objectives or desired outcomes for involving these groups in 
CPG development. 
This study was designed to gather this information from published CPGs, documents 
describing how they were developed, and interviews with professionals involved in CPG 
development.  
The creation of patient resources served as one of the only strategies of HCC 
involvement used for CPGs included in this study. HCCs were also involved in the 
dissemination of one of the CPGs included in this study. Even though very little had been 
done to involve HCCs in the development of CPGs included in this study, within the data 
sources analyzed, including web-based materials and information collected through 
interviews or questionnaires, there was discussion of new (implemented since the release 
of CPGs included in this study) or planned strategies for the involvement of HCCs in 
CPG development. These strategies have been implemented since the publication of the 
CPGs included in this study and are still being used currently, but they were not used in 
the development of the CPGs included in this study. For five of the CPGs included in this 
study, evidence of strategies to involve HCCs in CPG development could not be found, 
including strategies developed after their publication. 
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This chapter summarizes key results gathered for this study. A description of the 
data sample, and interview and questionnaire participants are provided. Descriptions of 
the few strategies used to involve HCCs in the development of the CPGs included in this 
study are also provided. Strategies implemented after the release of CPGs included in this 
study are also described. Individual strategies used to involve HCCs in CPG 
development, as well as new and planned strategies, are organized based on the stage of 
CPG development in which they have been or are employed. Finally, themes regarding 
the value of HCC involvement are presented. Important themes emerged regarding the 
perceived value and increased use of HCC involvement that could not be attached to any 
individual strategies of HCC involvement, but that described the practice in general. 
3.1 Data Sample and Participants 
Searches completed through PubMed and the CMA CPG Infobase revealed a total 
of twelve complete CPGs that were eligible for review in this study (Appendix B). 
Review of webpages corresponding to the CPGs included in this study revealed thirty-six 
documents relevant for analysis. These included guideline development protocols, patient 
engagement protocols, annual reports, author information summaries, initiative or 
program overviews, strategic frameworks, and newsletters. 
Five first authors and seven organizations were contacted to request participation 
in this study. An additional two CPG authors were contacted when responses were not 
received, in cases where this contact information was available. Two first authors agreed 
to participate through completing questionnaires, each representing a separate CPG 
included in this study. Four other professionals agreed to participate in interviews, 
representing four separate CPGs included in this study. Interview participants included a 
health research methodologist, a research coordinator, a research officer, and a quality 
improvement coach. One additional document relevant for analysis was collected from a 
research participant.  
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3.2 Strategies Used to Involve Healthcare Consumers, 
Organized by Stage of Clinical Practice Guideline 
Development 
This section describes individual strategies of HCC involvement in CPG 
development encountered through this study, including strategies used in the 
development of CPGs included in this study, new strategies, and planned strategies. 
Strategies encountered are organized by the stage of CPG development in which they are 
used. These stages include project planning, review of scientific literature, formulation of 
recommendations, reviewing and editing, and dissemination. HCCs were also involved 
throughout guideline development, and finally through the use of patient resources. 
Results are presented as individual strategies for involving HCCs in CPG development. 
Data sources utilized for this study did not contain enough detail to fully answer the 
research questions for each strategy encountered. The research questions are therefore 
answered for each strategy to the extent that this information was available. 
3.2.1 Project Planning 
Data analysis for this study revealed a two-part strategy implemented three years 
after the release of the corresponding CPG included in this study. This strategy was not 
used in the development of the guideline included in this study but is used currently in the 
development of new CPGs. In the first part of this strategy, patients are involved in 
project planning as part of a consultation group, separate from the main CPG 
development working group. Project planning is one of the first stages of guideline 
development, and involves defining a topic, determining research questions, deciding on 
the scope of the guideline development project, and drafting a project plan to describe 
this scope. A definition of the term “patient” could not be identified; however, this term 
was used to refer to the stakeholders involved through this strategy. Through data 
analysis it was noted that the consultation group is asked to review the project plan at the 
beginning of CPG development. Feedback is gathered through focus groups called 
“consultation group meetings”. Interviews replace focus groups when consultation group 
meetings involve only one participant. This strategy is utilized in order to increase the 
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likelihood that appropriate questions are asked and that the appropriate outcomes are 
examined, and to ensure that patient preferences and values are considered in the 
interpretation of evidence and the formulation of recommendations. The second part of 
this strategy, used in combination with this first part, is described in section 3.2.2. 
Results indicate that at the time one CPG included in this study was published, 
input from the general public was solicited during the process of topic selection for the 
development of new CPGs or the updating of existing CPGs. Topic selection involves 
determining topics that the overseeing organization will consider over the upcoming year. 
While this strategy was in place at the time the CPG included in this study was published, 
the general public did not contribute to the topic selection for this guideline. Information 
reviewed for this study indicated that this strategy remains in use. Further information 
regarding this strategy could not be found. 
3.2.2 Review of Scientific Literature 
Data analysis revealed one strategy for involving HCCs in CPG development that 
is the first part of a three-phase process and takes place during the review of scientific 
literature. The review of scientific literature informs the content of the guideline being 
developed, including its recommendations. This strategy is used currently in the 
development of CPGs but was implemented four years after the release of the 
corresponding CPG included in this study. Patients, family members, and informal 
caregivers are involved in CPG development through this strategy. In this context, 
patients are defined as the “intended targets of the guideline”, while family members and 
informal caregivers are defined as the “partners or caregivers of the intended targets”. 
Individuals belonging to these groups can participate in CPG development if they are 
“not practicing health care professionals”. Through data analysis, it was noted that the 
first phase of this strategy involves collecting information on patient preferences 
regarding screening outcomes, using a survey to rank pre-determined outcomes in terms 
of their importance for a particular screening procedure. In this strategy, participants are 
provided with information on outcome rankings by all other participants and then take 
part in a focus group to discuss their preferences. Data reviewed for this study indicated 
that within a week of having participated in this focus group, participants fill out a 
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survey, identical to the one used previously, to confirm their outcome rankings. Results 
gathered during this phase are used to inform the evidence review completed by members 
of the CPG development working group. Patients, family members, and informal 
caregivers are involved in this phase to facilitate the incorporation of patient preferences 
in the ranking of outcomes of interest for a guideline. These results also partially inform 
the content of knowledge translation tools meant for patient use (described in section 
3.2.7). 
3.2.3 Formulation of Recommendations 
The second part of a three-part process that has been implemented since the 
release of the corresponding CPG included in this study involves patients, family 
members, and informal caregivers in the formulation of recommendations. The first 
phase of this strategy is described in section 3.2.2. Patients are defined as the “intended 
targets of the guideline”, while family members and informal caregivers are defined as 
the “partners or caregivers of the intended targets”. Participants are provided with 
information from the previously completed systematic review in order to inform them of 
the relative likelihood of achieving each listed screening outcome. With this information, 
participants are again asked to rank pre-determined outcomes in terms of their importance 
for a particular screening procedure. Participants are again provided with information on 
outcome rankings by all other participants and take part in a focus group to discuss their 
preferences. Again, within a week of having participated in this focus group, participants 
fill out a survey identical to the one used previously, to confirm their outcome rankings. 
Results gathered through this phase are used to inform the final recommendations within 
CPGs being developed. Results gathered through this phase also inform the content of 
knowledge translation tools accompanying the CPG being developed. These patient 
resources are described in section 3.2.7. Patients, family members, and informal 
caregivers are involved in this phase to facilitate the incorporation of patient preferences 
in the ranking of outcomes of interest for a guideline.  
In another strategy found through this study, patients are allowed to be involved 
in CPG development as part of a consultation group. This strategy is the second part of a 
two-phase process. The first phase of this strategy is described in section 3.2.1. This 
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strategy was implemented three years after the publication of the CPG included in this 
study and is used currently in the development of new CPGs. The consultation group 
from the first phase is asked to review draft recommendations to be included in the 
published CPG and provide feedback throughout a focus group meeting. Interviews 
replace focus groups when focus group meetings involve only one participant. This 
strategy is utilized in order to increase the likelihood that appropriate questions are asked, 
that the appropriate outcomes are examined, and to ensure that patient preferences and 
values are considered in the interpretation of evidence and formulation of 
recommendations. The organization that developed this strategy assessed it for usability 
and concluded that when both parts of this strategy are used together, the strategy is 
feasible and effective for involving patients in CPG development.  
3.2.4 Reviewing and Editing 
Data analysis revealed one new strategy that allows for the potential to involve 
HCCs in CPG reviewing and editing, through a public review process. This strategy was 
implemented four years after the release of the CPG included in this study, and so was 
not utilized through its development. However, this strategy is in use currently. Through 
this strategy, HCCs can take part in an external review process that facilitates peer review 
and the finalization of CPGs, before they are published. Clinical practice guidelines are 
placed online, and can be accessed and reviewed by anyone. Individuals can access CPG 
materials made available for external review and fill out a questionnaire to comment on 
how a particular guideline could be improved. Alternatively, draft versions of CPGs 
under review are mailed to a random sample of physicians, nurse practitioners, and “key 
stakeholders”. As part of this process, HCCs can provide feedback through stakeholders 
asked to participate in this review. Theoretically, any group of HCCs can contribute to 
this review process, although this strategy does not actively seek input from any one 
group of HCCs. Because CPG materials are placed online or mailed to key stakeholders 
primarily to facilitate review by professionals such as clinicians, this strategy of HCC 
involvement is unintentional. Healthcare consumers can participate in this process only as 
a result of draft material being made publicly available. The stated purpose of seeking 
48 
 
feedback in this manner, including allowing HCCs to provide feedback, is to ensure that 
guidelines are clear, usable, and error-free.  
Data analysis revealed another strategy for HCC involvement that is being 
considered, but has not been put into practice at the time that data collection was 
completed for this study. When this strategy is put into use, the general public will be 
involved in the process of CPG reviewing and editing. Clinical practice guidelines will be 
posted to the organization’s webpage to allow members of the general public to post 
comments. Alternatively, members of the general public will be able to submit 
information regarding their personal areas of interest. This will allow these individuals to 
receive draft CPGs related to their areas of interest so that they may review them and 
provide feedback. The organization will involve HCCs in this way with the intention of 
ensuring that patient preferences and values are considered in the formulation of final 
recommendations. 
Finally, one strategy was implemented four years after the release of the 
respective CPG included in this study but has since been used in the development of only 
one CPG. In this strategy, both patients and informal caregivers were involved in CPG 
development as part of the “target audience” for these guidelines. Detailed definitions for 
the target audience involved in this process were not provided. These stakeholders were 
provided with outlines of four draft CPGs, each pertaining to different substance use 
disorders, and asked to provide feedback on these CPGs. The rationale for involving 
patients and informal caregivers was not provided. It is not clear if this strategy will be 
used in the future by the respective CPG developer. 
3.2.5 Dissemination 
Data analysis for this study revealed that HCCs are involved in the dissemination 
of CPGs. Dissemination is the final stage of CPG development and involves publishing 
and distributing the finalized CPG. As part of the process of dissemination for one CPG 
included in this study, HCCs were involved in a “quality improvement” initiative related 
to the corresponding CPG included in this study. In this case, quality improvement 
initiatives are used to provide support for applying CPGs within clinical practice. A 
redesign of this process led to the involvement of patients. Patients were involved in 
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order to gather their perspectives on how research evidence and information contained 
within the CPG should be applied in practice. Involving patients in this initiative was 
done to gather perspectives and strategies for improving care for patients. This strategy 
was not meant to inform only the development of the specific CPG included in this study, 
but instead to inform all knowledge translation efforts made by the overseeing 
organization. Furthermore, involvement of patients in similar dissemination initiatives 
has not been made a standard part of guideline development, and it is unclear whether 
this strategy has been used in the development of other guidelines. 
One strategy involved the use of “community-based dialogue workshops” during 
CPG dissemination. This strategy was not used in the dissemination of the CPG included 
in this study. Instead, it was only used in the dissemination of one separate CPG that was 
published four years after the release of the CPG included in this study. For this strategy, 
patients participated in focus groups, in order to educate these stakeholders on draft 
recommendations. Patients were defined as “older adults” in this context. Feedback was 
also gathered on the potential for further dissemination activities, including where 
community members may have wanted to learn about these guidelines. As indicated 
previously, this strategy has only been used in the dissemination of one CPG at the time 
that data collection was completed for this study, and it is not clear if this strategy will be 
used in the development of future guidelines. 
3.2.6 Throughout Clinical Practice Guideline Development 
Analysis of related materials for one CPG included in this study revealed an 
“iterative” process for engaging key stakeholders throughout the CPG development 
process. This process was not used in the development of the corresponding CPG 
included in this study but is currently used in the development of CPGs. The general 
public is involved through this strategy, in order to gather unique and important 
perspectives on the organization’s activities. Healthcare consumer involvement is utilized 
at various stages of CPG development, including selection of guideline topics and 
outcomes, and while gathering information on patient preferences. Feedback is collected 
from members of the general public through use of questionnaires, interviews, focus 
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groups, and online surveys. Further information regarding the details of these procedures 
were not found.  
A separate strategy to involve HCCs throughout CPG development was 
implemented three years after the publication of the respective CPG included in the 
primary dataset for this study. This strategy was therefore not used in the development of 
this CPG but is used currently. This strategy is designed to involve patients as active 
members of CPG working groups. This strategy involves patients in every aspect of CPG 
development. The organization that utilizes this strategy does so in order to increase the 
likelihood that appropriate questions are asked, that the appropriate outcomes are 
examined, and to ensure that patient preferences and values are considered in the 
interpretation of evidence and formulation of recommendations. A definition of the term 
patient could not be identified; however, this term is used to refer to the stakeholders 
involved through this strategy. The organization that developed this strategy assessed it 
for usability and concluded that this newly proposed model was both feasible and 
effective for involving HCCs in CPG development. 
3.2.7 Use of Patient Resources 
This section provides descriptions of patient resources developed to accompany 
CPGs. Patient resources are an important strategy of consumer communication as 
described by Rowe & Frewer (2005). Three CPGs included in this study are accompanied 
by a patient resource meant to educate patients on their choices for treatment or other 
resources at their disposal. For one of these CPGs, the creation of patient resources is a 
typical part of CPG development. For two CPGs included in this study, a patient resource 
was not created even though this was a normal part of the CPG development process for 
the overseeing organizations at the time of their release.  
One strategy uncovered through data analysis involves HCCs through the use of 
knowledge translation tools meant to accompany CPGs. The organization that creates 
these tools described their use in a procedures manual published one year after the release 
of the CPG included in this study. These tools include CPG summaries, frequently asked 
question sheets, and patient decision aids. These tools can be developed for use by 
patients and the general public. In documents describing this strategy, the term “patient” 
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is used to refer to users of the healthcare system. Each of these resources is created in 
order to improve the use and impact of published CPGs as well as educate patients on 
their content. However, knowledge translation tools meant for patient use were not 
created for the CPG included in this study. Although not considered a strategy for 
involving HCCs in CPG development, patients, family members, and informal caregivers 
are involved in the development of knowledge translation tools when they are meant for 
patient use. Content of these resources is informed by the first two phases of a three-
phase process for involving HCCs, as described in sections 3.2.2 and 3.2.3. These 
stakeholders also contribute to reviewing and editing these resources.  
Analysis of one CPG included in this study revealed a patient resource that was 
created in collaboration with a separate national research program. This patient resource 
was created two years after the release of this CPG but is meant to accompany this 
guideline. This patient resource contains “practical information” and was developed in 
order to provide educational material to patients and informal caregivers regarding 
options available for treating depression. Patients and informal caregivers are defined as 
“people with lived experience” with depression, the target illness of the corresponding 
CPG. Informal caregivers were additionally referenced to as “caregivers”, who are 
distinct from professional “healthcare providers”. Providing information on treatment 
options is done to empower patients and facilitate shared-decision making between 
patients and healthcare providers in clinical settings. As a resource that was developed 
after the initial publication of the corresponding CPG, this resource was developed as part 
of the dissemination and updating of the guideline. 
Another organization has indicated that patient resources are developed “when 
relevant”. These patient resources are developed for use by patients, during the 
dissemination of certain guidelines, although no details describing when these materials 
are considered relevant were found. Furthermore, a patient resource had not been made 
available for the CPG analyzed for this study at the time data analysis was completed.  
A brochure was developed to accompany a separate CPG included in this study, 
two years after its most recent update. This brochure is a patient resource created for use 
by patients and family members in order to help improve the lives of patients living in 
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long term care, as well as improve the lives of their family members. As a patient 
resource developed from the updated guideline after the time of its publication, this 
patient resource was developed as part of the dissemination and updating process for this 
guideline. It is not clear if the overseeing CPG developer creates these patient resources 
for each CPG it publishes. However, similar patient resources have been created for the 
topic areas of delirium, depression, and the prevention of suicide since the release of the 
CPG included in this study. Each of these patient resources was developed based on 
material from previously published CPGs focused on the same topic areas. These patient 
resources contain frequently asked questions and a resource guide. Each of these patient 
resources were developed to inform patients and family members on the diagnosis and 
treatment of a specific mental illness, and additional resources through which patients 
and their families can seek help or provide help to the individual suffering from the 
illness in question.  
For another CPG included in this study, a patient resource, called a “resource 
guide”, was made available as part of the CPG document itself. This resource contains 
information on resources for support services, self-care, and suicide prevention for 
individuals suffering from depression. Similar resources have been created for other 
CPGs produced by the same CPG developer. The organization that created these patient 
resources indicated that they are meant for use by patients, in order to outline health 
system services and resources available in the province in which these resources are 
meant to be used. This organization also published an annual report, four years after the 
publication of the CPG included in this study. This report indicated that work has been 
done to standardize the approach used by this organization to create patient resources. 
This report included recommendations to create patient resources on a limited basis. 
Further details of this strategy could not be found. 
3.3 Summary of Strategies Used to Involve Healthcare 
Consumers in Clinical Practice Guideline Development 
 To summarize, three CPGs analyzed in this study were accompanied by patient 
resources. The organizations responsible for the development of three CPGs included in 
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this study develop patient resources as a normal part of their CPG development process, 
but two of these failed to do so for the CPG included in this study. Patients, family 
members, and informal caregivers have been the intended targets of these resources, and 
they have included such tools as decision aids, frequently asked question sheets, resource 
guides, and guideline summaries. These tools are created to educate patients on treatment 
options and available resources. These tools are also seen as helpful in facilitating shared 
decision making in clinical consultations, and in improving the use and impact of the 
accompanying CPG. Healthcare consumers were also involved in the dissemination of 
one CPG included in this study, in order to identify patient perspectives on how the CPG 
should be applied to practice. In total, only four CPGs analyzed in this study involved 
HCCs in their involvement. One additional strategy was in place at the time the 
corresponding CPG included in this study was published, but was not used in the 
development of this guideline. This strategy is still used, and involves the general public 
in CPG topic selection. 
 Furthermore, several strategies for HCC involvement have been implemented 
since the release of the CPGs analyzed in this study. These strategies are being used 
currently but were not used in the development of the CPGs that made up the primary 
data sample for this study. Patients, family members, and informal caregivers are now 
involved in the design and review of literature searches conducted to inform guideline 
content and in the formulation of their recommendations. In addition, patients are 
involved as active members of development groups, throughout all stages of their 
development. Patients might also have been involved in the process of CPG reviewing 
and editing. In one strategy, involving HCCs during the process of reviewing and editing 
is not intentional, and is only a possibility for CPGs produced by the respective 
organization, given that they post their draft CPGs publicly as part of their call for expert 
feedback. Involving HCCs in the process of CPG development in these ways is done in 
order to ensure that patient preferences are incorporated into CPG content. HCCs are also 
involved in CPG development in order to gather unique perspectives from these 
stakeholders, identify appropriate outcomes for treatment, and to educate these 
stakeholders on recommendations for treatment. 
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3.4 The Use and Value of Healthcare Consumer 
Involvement in Clinical Practice Guideline Development 
Key themes emerged regarding the increasing use of HCC involvement in CPG 
development and the perceived value of this practice. Information contributing to these 
themes was collected from interviews only and does not correspond to specific strategies 
used to involve HCCs in CPG development. Information collected through interviews has 
therefore been considered independently from other data sources used in this study. This 
section presents results gathered that described the increasing use of HCC involvement in 
CPG development, and the value of the practice in general. 
3.4.1 Theme One: Efforts to Involve Patients in Clinical Practice 
Guideline Development are Increasing, but Best Approaches 
are Unclear 
 Information collected through interviews confirmed that HCCs were not involved 
in the development of the CPGs corresponding to these interviews, indicating that at the 
time of their release, HCC involvement was poorly utilized. One participant indicated 
that their organization usually involves patients in their initiatives, including in CPG 
development, but this practice was not utilized for the CPG analyzed in this study. Why 
HCCs were not involved in the development of this guideline was unclear to the research 
participant. Furthermore, another organization had performed literature searches to 
collect information on patient preferences and values within a particular CPG’s topic 
area. However, in the majority of these cases, HCC involvement was not part of the 
normal development process used to develop CPGs.  
 Since the release of the CPGs analyzed in this study, CPG developers have begun 
to implement strategies for involving HCCs in their CPG development procedures or 
have looked to improve upon their existing strategies. One participant had indicated that 
patients or other groups of HCCs were never intentionally involved in their respective 
organization’s CPG development process. However, this participant described an 
ongoing “pilot project” meant to involve patients in CPG updating, as well as in the 
development of “patient-facing” materials to accompany that CPG. Another organization 
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has since developed a strategy for involving patients in their CPG development processes 
in response to emerging evidence regarding its benefit, as well as calls for its integration 
into CPG development: 
“So they were basically taking steps to align themselves with the patient 
engagement standards, the ones established by, I think its AGREE… the 
Appraisal of Guidelines for Research and Evaluation. So they had called for 
patient involvement in the guideline development process… basically, they were 
taking steps to align themselves with the best available evidence at the time” 
These efforts to incorporate recommendations and evidence for the benefits of HCC 
involvement have only been made since the release of the CPG analyzed for this study.  
 In other organizations, changes in system design lead to alterations to strategies 
used to involve HCCs in CPG development: 
“And then [the organization] changed and there were no disease site groups, so 
the way that we developed guidelines and how guidelines were produced weren’t 
coming from the disease site groups. Usually the disease site groups decided that 
there was a topic that was of interest and very important, and that was how we 
decided what guidelines we were going to do. And now there is a different 
process from [the organization] where a group of people decide what guidelines 
are very important and need to get developed. So that was one difference, so then 
we didn’t have a patient on each disease site group. So then, the director of [the 
clinical practice guideline development program], she decided to do a study on 
different models of how to engage patients since they weren’t on the disease site 
groups, how were we going to get patients involved in guidelines.” 
As the systems put in place to develop CPGs have changed, there have been continued 
and increasing efforts to involve HCCs in these systems. One organization has also 
implemented their first strategy for involving HCCs in the development of CPGs as part 
of a quality improvement approach in recent years. This quality improvement approach 
involved patients in a discussion to identify what measures could be taken to improve the 
use of an individual CPG. Involving patients in this quality improvement approach has 
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not been made a standard practice, but the organization that utilized this strategy is 
considering further opportunities for involving these stakeholders. 
 Although each CPG developer represented by an interview participant has 
developed strategies for involving HCCs in their CPG development procedures, 
professionals who participated in interviews expressed concern that the optimal strategies 
for doing so remain unclear. Participants indicated that neither they nor their respective 
organizations were informed on best-practices for involving HCCs in CPG development 
and indicated that examples of what has worked in the past could help them set up their 
own strategies. In cases where organizations have developed strategies for involving 
HCCs in CPG development, challenges have been encountered in the recruitment 
process. Patients or family members are reluctant to contribute to the development of 
CPGs for illnesses with which they have no experience. Ensuring minority groups or 
people living outside of urban areas have adequate representation is also a challenge. 
Finally, patients and family members struggle to meet time commitments needed to 
participate in CPG development while dealing with work, family lives, and contending 
with their illness.  
3.4.2 Theme Two: Patient Involvement in Clinical Practice 
Guideline Development Leads to Identification of Important 
Issues 
 For those professionals who participated in interviews, the perceived value of 
involving HCCs in CPG development centers around incorporating patient preferences 
and values into information contained within the CPG. One participant pointed out that 
incorporating HCCs in the CPG development process ensures that “patient preferences 
and opinions are considered”. Another participant indicated that patients can “identify 
additional outcomes that are important to them, that the working group hadn’t thought of, 
or didn’t realize were as important as patients actually declare them to be”. Incorporation 
of patient preferences and values is perceived to improve the applicability and quality of 
CPGs. 
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 Although participants agreed that involving HCCs in CPG development should 
help to identify additional information that should be incorporated into CPGs, 
perspectives regarding how this should be utilized differed between participants. One 
participant indicated that information taken from patients could be integrated directly into 
recommendations included within CPGs: 
“…their perspective was very important in terms of keeping us focused, what was 
important on the recommendations, like what was the end point of the 
recommendations to ensure that things are clear and concise and really helpful for 
the patient. And that’s the purpose of the guidelines right, is to help patients so, 
patients always need to be considered and remembered, not just the data.” 
The participant indicated that HCC involvement facilitates the consideration of patient 
preferences and values during review of evidence and formulation of recommendations 
and is therefore helpful for identifying the appropriate treatment outcomes that a CPG 
should focus on. Another indicated that information collected from patients should be 
utilized to guide literature reviews done before recommendations are formulated.  
 Finally, another participant indicated that patient involvement in CPG 
development should be done in order to identify gaps in the information being 
incorporated into CPGs. This participant stated that HCC involvement was not done as a 
“check and balance”, indicating that involvement isn’t focused on patient empowerment. 
In this case, the exact value of HCC involvement was instead identifying assumptions 
made by professionals during the CPG development process, rather than identifying 
issues important to patients. Having patients to identify, question, and address these 
assumptions was perceived to help create more detailed and clear CPGs. This participant 
was therefore focused on the identification of information that can make CPGs more 
usable both for patients and professionals. Furthermore, this participant did not indicate 
that patient input was useful within any individual stage of CPG development, but instead 
could be utilized throughout development to identify gaps in the information put into the 
CPG.  
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Chapter 4  
4 Discussion 
This chapter provides a summary of results of this study and discusses their 
implications for the practice of involving healthcare consumers (HCCs) in clinical 
practice guideline (CPG) development. A summary of important reflexive notes gathered 
throughout this research project is also presented. The study limitations and directions for 
future research are provided, and finally, the author’s conclusions are discussed. 
4.1 Implications 
To the best of the researcher’s knowledge, this is the first study to describe the 
strategies used to involve HCCs in CPG development within Canada. Results of this 
study add to our understanding of how HCCs are involved in the development of CPGs 
for mood and anxiety disorders within Canada, what groups are involved, and why they 
are involved.  
Healthcare consumers were involved in the development of only four CPGs 
included in this study. Healthcare consumers were involved in the development of three 
CPGs included in this study through the use of patient resources. These resources were 
created in order to educate patients, family members, and informal caregivers regarding 
what resources are at their disposal for helping them manage their illnesses. Patient 
resources were also used to improve the use of the corresponding CPGs, and facilitate 
shared decision making. Healthcare consumers were also involved in the dissemination of 
one guideline included in this study in order to identify how the guideline could be 
applied in practice.  
Additional strategies to involve HCCs in CPG development were found, but the 
majority of these were developed only after the release of the CPGs included in this 
study. Strategies currently used to involve HCCs in CPG development vary. Patients, 
informal caregivers, family members, and the general public are involved in the review of 
scientific literature, the formulation of recommendations, the review of draft guidelines, 
and throughout CPG development. These stakeholders are involved in these stages in 
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order to facilitate the consideration of patient preferences and to identify appropriate 
outcomes for treatment or screening. An examination of documented CPG development 
procedures revealed that HCCs are not involved in the normal development procedures 
for five of the twelve CPGs analyzed in this study. Overall, HCC involvement is used 
primarily to identify issues that are important to patients, and utilization of the practice is 
increasing. 
Results of this study suggest that currently, HCCs are inconsistently involved in 
CPG development. For example, five CPGs included in this study did not involve HCCs 
in their development, and their analysis did not reveal any strategies that have been 
implemented since their publication. Furthermore, there was little overlap in the 
strategies that were identified through this study. The inconsistent involvement of HCCs 
in CPG development outlined in this study mirrors results found through similar studies 
completed outside of Canada. Failing to involve HCCs in CPG development has been 
described as a missed opportunity (Armstrong & Bloom, 2017). Involving HCCs in CPG 
development can help to increase the quality of guidelines being produced. For example, 
research has been done to prove that involving patients leads to the incorporation of 
important topics within these tools (Armstrong et al., 2017; Armstrong et al., 2018; Tong 
et al., 2012). Avoiding HCC involvement in CPG development can mean that guideline 
developers miss the opportunity to take advantage of these benefits. As a result, CPGs 
being developed may be of lower quality. 
There was little opportunity for HCCs to contribute information directly to the 
CPGs included in the primary data sample of this study. However, the use of patient 
resources was a common strategy of HCC involvement for these CPGs. These resources 
have been shown to be useful for patient education and should continue to be created to 
accompany CPGs (Stacey et al., 2014). Creating patient resources to accompany CPGs 
does help to disseminate information to patients, their family members and informal 
caregivers, which agrees with the desired benefits of patient resources encountered 
through this study. However, when these resources are the only form of HCC 
involvement utilized, many of the purported benefits of HCC involvement are still 
missed. As tools for patient education, these resources only allow for the transfer of 
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information from professionals to HCCs, falling into the category of consumer 
communication (Rowe & Frewer, 2005). These resources therefore do not allow for an 
ongoing dialogue between HCCs and professionals. Patients and other groups are not 
given opportunity to raise their concerns while the corresponding CPG is being 
developed. Their knowledge of patient preferences and values may therefore remain 
missing from the content of CPGs. Furthermore, involving patients in the dissemination 
of CPGs in order to identify how the guideline should be implemented into practice might 
not lead to the incorporation of information from these stakeholders into the guideline. 
Although this strategy would allow for the flow of information from HCCs to 
professionals, this transfer would take place only after the guideline had been completed. 
It is therefore unlikely that this would have had an effect on the content of the CPG, and 
that many of the purported benefits of HCC involvement in CPG development were 
missed. 
Although there was little opportunity for HCCs to contribute information to the 
CPGs included in this study, many strategies have been implemented since the 
publication of these CPGs. However, some of these strategies still have shortcomings. 
Not all of these strategies involved a range of stakeholders, and others involved HCCs at 
single or isolated points throughout CPG development. Strategies that have involved only 
one type of HCC through one stage of CPG development miss the opportunity to gather 
perspectives from different groups with potentially different priorities. Furthermore, by 
failing to encourage an ongoing interaction between HCCs and professionals, these 
strategies allow for only the transfer of information from HCCs to professionals (Rowe 
and Frewer, 2005). These strategies may miss the opportunity for professionals to provide 
feedback to HCCs and for HCCs to subsequently continue to advocate for their own 
interests. As a result, information gathered from HCCs may not be fully considered and 
incorporated into final CPG materials. However, HCC involvement is likely to be less 
resource intensive when it is achieved through the use of individual focus groups or 
interviews at specific points of the CPG development process, as opposed to allowing for 
continued interactions between professional stakeholders and HCCs. The reduced 
demand for time and resources offered by these strategies may warrant their continued 
use, as long as input gathered through these strategies is adequately considered. 
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The increasing use of HCC involvement in CPG development could be a result of 
the increasing recognition of the potential value of the practice. Results of this study 
suggest that recommendations from authoritative organizations have motivated CPG 
developers to involve patients and the public in their CPG development procedures. As 
research continues to develop evidence for the usefulness of HCC involvement, and 
authoritative organizations continue to publish recommendations for its use, HCC 
involvement in CPG development is likely to continue to increase. Furthermore, results 
of this study suggest that greater clarity regarding how HCCs should be involved in CPG 
development would be beneficial for its use. Enlarging and clarifying the body of 
evidence regarding the usefulness of involving HCCs in CPG development may help to 
resolve skepticism surrounding the practice and allow CPG developers to feel confident 
in its utility. Providing further information on the most efficient methods for involving 
HCCs in CPG development may also contribute to the adoption of this practice by aiding 
CPG developers in designing their own strategies.  
 Even with the current uncertainty surrounding best practices for its use, there 
remain “principles-based” reasons for involving HCCs in CPG development that can 
rationalize the use of the practice. There are benefits to this practice that reflect the values 
of a democratic society, including emphasizing patient autonomy, and encouraging the 
democratic rights of patients and members of the public as taxpayers (GIN, 2015). 
Additionally, HCCs should be involved in the development of CPGs in order to empower 
these stakeholders and enable them to work as partners with healthcare providers in the 
design and delivery of health services (van de Bovenkamp & Trappenburg, 2009). 
Organizations that develop CPGs within Canada should strive to involve HCCs in CPG 
development in order to make the process of CPG development reflect these values. A 
greater focus on the value of these benefits could help to increase the use of HCC 
involvement in CPG development. 
 Descriptions of how HCCs have been involved in CPG development provided 
through this study can be used in the future to guide CPG developers in designing and 
implementing their own strategies. Evidence continues to build regarding the beneficial 
effects of HCC involvement on the content and scope of CPGs, and the subsequent 
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effects the practice can have on the impact and usability of these guidelines, including 
their ability to encourage patient-centered care. As stronger evidence for the benefit of 
HCC involvement emerges and according changes are made to advisories on how to 
develop high-quality CPGs, HCC involvement may continue to increase, both within 
Canada and in other nations. As this evidence builds, a stronger focus on the principles-
based benefits of HCC involvement may help to improve use of this practice in the 
present. 
4.2 Study Limitations 
This study used a qualitative descriptive methodology in order to describe how 
HCCs are involved in CPG development within Canada. Qualitative description is 
commonly used to produce interpretations of data that are “data-near” or that produce 
pure descriptions of a given dataset (Neergaard, 2009). However, this methodology has 
been criticized for its avoidance of the use of theory (Neergaard et al., 2009; 
Sandelowski, 2010). Although this study utilized previous theory to inform the extraction 
of relevant information from the dataset, only general descriptions of HCC involvement 
in CPG development are given. Descriptions are left in general terms and are not 
integrated directly back to existing theories regarding patient and public involvement. 
Instead, only descriptive summaries are given. 
There are some limitations to the methods used that may have impacted the level 
of detail in the descriptions of HCC involvement provided by this study. First, interviews 
and questionnaires were utilized to supplement information uncovered from CPGs and 
related web-based materials. Interviews were completed for four CPGs included in this 
study, and questionnaires for an additional two. For the remaining six CPGs, the only 
sources of data were the CPG documents themselves and the related web-based material. 
Publicly available material, including CPG documents and web-based documents, may 
not have referenced every strategy of HCC involvement utilized. In these cases, strategies 
used to involve HCCs in CPG development that were not described in publicly available 
websites or documents would not have been analyzed in this study. Furthermore, for 
many of the strategies described in this study, the sources of information that were 
accessed did not provide adequate detail to fully answer the research questions. As a 
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result, some details of how HCCs are involved in CPG development, including the type 
of HCC involved, the stage in which they are involved, or the reason for their 
involvement could not be identified for each strategy. Finally, several organizations 
provided descriptions of involving patients or other lay members of the public in their 
programming but did not explicitly describe how this related to involving these 
stakeholders in CPG development. These descriptions were not reported for this study, as 
it was not possible to link these strategies for patient and public involvement directly to 
the processes of CPG development. 
 In order to facilitate the collection of results directly from professionals involved 
in CPG development in Canada, interviews and questionnaires were completed with 
professionals of varying backgrounds. Authors of two of the CPGs included in this study 
completed questionnaires that were less flexible and potentially less detailed than 
interviews. Interviews were completed with professionals involved in research 
coordination or quality improvement at the respective organization that developed CPGs 
included in this study. Each of these professionals had different roles in the process of 
CPG development at their organization. This could have contributed to differences in 
their experiences with, and perspective on the value of HCC involvement in CPG 
development, or in their knowledge of how HCCs are involved in CPG development at 
their organization. 
Theoretical saturation occurs when new information collected from a qualitative 
sample informs existing findings but does not add anything new to them (Milne & 
Oberle, 2005). Although difficult to achieve, theoretical saturation is an important factor 
contributing to the rigour of a qualitative descriptive study (Milne & Oberle, 2005; Tracy, 
2010). Clinical practice guidelines were used as the primary data sample for this study in 
following with what had been done in previous, similar studies (Armstrong & Bloom, 
2017). Utilizing CPGs as the primary data sample allowed for efficient identification of 
organizations that develop CPGs. However, this study was limited to analyzing CPGs 
pertaining to the management of mood and anxiety disorders in order to ensure the data 
sample could be analyzed within a Master’s thesis timeframe. As a result, only twelve 
CPGs were analyzed in this study. Because this study’s sample size is limited, it is likely 
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that other organizations excluded from review in this study utilize different strategies for 
involving HCCs in CPG development. Furthermore, the strategies used to involve HCCs 
in the development of the CPGs included in this study have been limited to those applied 
to the development of CPGs pertaining to mood and anxiety disorders. It is possible that 
different strategies are used for CPGs developed for other types of disease or illness. 
Finally, organizations that have developed CPGs for the management of mood and 
anxiety disorders may have also been left out of this study if, for example, they have not 
created a CPG that adhered to this study’s inclusion criteria. Organizations were left out 
of consideration if they had contributed only to the funding or endorsement of a CPG 
included in this study. Additional organizations credited in the development of CPGs 
included in this study were left out if they had only contributed to the creation of a 
literature review protocol, the process of CPG editing, or the publication of the CPG. 
Because of this, this study may not report some strategies used to involve HCCs in the 
development of CPGs specifically for mood and anxiety disorders. For these reasons, it is 
unlikely this study has achieved theoretical saturation in describing how HCCs have been 
involved in CPG development in Canada. 
4.3 Directions for Future Research 
Awareness of the value of the practice of involving HCCs in CPG development is 
increasing (Boivin et al., 2010). The results of this study, along with those of past 
research, indicate that there is room for improvement in utilizing this practice (Armstrong 
& Bloom, 2017). This study has provided insight into the strategies that are used to 
involve HCCs in CPG development. This information can be used by organizations that 
have not yet considered the practice or are in the process of developing their own 
strategies for doing this. It has also provided some insight into the perceived value of the 
practice. There remains a gap in research that evaluates the effectiveness of these 
strategies, or that outlines the facilitating factors that improve HCC involvement in CPG 
development, or the challenges that may inhibit its use. Future research should address 
each of these gaps. 
There remains some criticism surrounding the idea of involving HCCs in CPG 
development, including the idea that involving these groups may be tokenistic given the 
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challenges involved in gathering meaningful input, such as concerns regarding the ability 
of lay persons to understand scientific terminology, or the effects of perceived power-
imbalances on willingness to contribute (Légaré et al., 2011; van de Bovenkamp & 
Zuiderent-Jerak, 2015). Furthermore, alternative options exist for gathering information 
on patient preferences and values, such as through gathering this information from 
existing research (Fraenkel et al., 2016). Because bringing HCCs in to contribute to CPG 
development can be a time- and resource-intensive process, it may be more efficient to 
gather information on patient preferences and values as part of the literature review. A 
final concern is that incorporating evidence regarding patient preferences, directly from 
these stakeholders or otherwise, may hinder the consideration of patient preferences and 
values in individual clinical consultations (van de Bovenkamp & Trappenburg, 2009). 
Research should be conducted to establish the validity of these issues and how they may 
be overcome of present. 
Even with these potential issues, previous studies have pointed out that involving 
patients in CPG development leads to identification of important material that should be 
included in CPGs (Armstrong et al., 2018; Tong et al., 2012). Similar studies will be 
needed to verify the generalizability of these results and to further demonstrate the effects 
that HCC involvement can have on CPG content. In addition, there remains a large gap in 
our knowledge of the potential benefits of HCC involvement in CPG development. 
Future research should aim to determine the connections between HCC involvement in 
CPG development, improved focus on patient-centered care in clinical consultations, and 
the resulting improvements in health outcomes. The impact of HCC involvement on the 
usability of CPGs, and their responsiveness to individual patient needs should also be 
addressed in future research. Further research will also be needed to determine whether 
HCC involvement can help reduce the effects of professional biases or conflicts of 
interest on CPG content. 
 As a separate concern from evaluating the effectiveness of involving HCCs in 
CPG development, future research should also add to previous work done in evaluating 
the effects of certain facilitating factors. Previous research has identified how patients 
may be more effectively involved in CPG development, including through providing 
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training to help them understand the overall process of CPG development and the 
specialized terminology that is used throughout the development process. Patients may 
also be asked to provide feedback at specific points in the development process, or to 
contribute at specific working group meetings, in order to avoid issues related to time-
commitments for these stakeholders. Future research will have to identify the most 
efficient strategies for involving HCCs in CPG development. Providing this information 
to organizations that develop CPGs may encourage the use of the practice. This study 
provides insight into some of the details of HCC involvement that can be changed to help 
guide this research. In addition, further research should evaluate the value of involving 
specific patient populations in CPG development. For example, elderly patients may be 
involved as they demonstrate a greater variance in preferences and values compared to 
younger patients (Jansen et al., 2015). 
 Finally, future research should evaluate the effects of HCC involvement in CPGs 
for different types of illness and disease. Some authors have suggested that involving 
HCCs in CPG development may be more beneficial for those illnesses that have little 
perceived effects, but whose treatments come with perceived side effects, such as in 
various forms of cardiovascular diseases (Albarqouni, Doust, Glasziou, 2017; Yebyo, 
Aschmann, Yu & Puchan, 2018). Treatment of these illnesses may require a greater 
emphasis on patient preferences to achieve an effective treatment plan. More information 
is needed regarding the benefit of involving HCCs in development of CPGs meant for 
mood and anxiety disorders specifically. Future research should therefore work to 
identify whether involving HCCs has differing impacts on the usability and the outcomes 
of use for CPGs for different types of illness or disease. 
4.4 Personal Reflection 
I completed my undergraduate degree with a double major in Physiology and 
Pharmacology. I began my studies in the Master of Health Information Science program 
in the hopes that I could build my knowledge of public health and of the healthcare 
system, to better prepare myself for a career in medicine. Completing this thesis, and the 
Master of Health Information Science program, has been a wonderful learning experience 
that I believe will be essential in determining the direction of my future career. The 
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Interdisciplinary Issues in Health Information Science and Knowledge Translation 
classes confirmed my interests in evidence-based medicine and in patient and public 
involvement in research and in health services and policy development. I hope to be able 
to continue to advocate for patient and public participation in my future career and build 
upon existing evidence for its benefits through research.  
The Canadian Health Policy course that I completed this past year has allowed me 
to explore my interests in public health and health policy, specifically surrounding access 
to healthcare amongst Indigenous populations in Canada. Furthermore, the opportunities I 
have had to present at conferences across Canada have ignited my passion for public 
health. Engaging with like-minded professionals who have accomplished so much in their 
careers and have contributed invaluable knowledge to the healthcare industry has been an 
inspiration. I look forward to my own career in healthcare in which I may build on these 
interests. I plan on expanding my research endeavours to include critical issues in public 
health, such as the growing opioid crisis, and the effects of climate change on public 
health. I especially look forward continuing to travel throughout Canada and the world, in 
order to talk about my own research, as well as learn from that of others. Overall, I am 
truly grateful for the opportunities I have had to explore issues across public health and 
healthcare services and policy development. 
Completing this thesis has also provided invaluable experience in the process of 
designing and conducting a research project. This project has exposed me to the 
expansive world of qualitative research methods. Through Gail Teachman’s Qualitative 
Research Methods course, I have had the opportunity to study some of the more common 
methodologies such as grounded theory, ethnography, and phenomenology. I was able to 
explore the complex paradigms, epistemologies, and ontologies that underline commonly 
used methodologies, and the overlap between each that compounds their complexity. I 
was also able to develop my ability to clearly articulate the paradigmatic underpinnings 
of a particular research study and understand the importance of doing so. The complex 
theory and unique terminology were often overwhelming; however, the value of 
qualitative research in establishing theories and hypothesis within the health and social 
sciences remained clear. Qualitative description remained an ideal choice for this 
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research project. I was able put qualitative research into practice using a methodology 
that required only minimal use of this complex theory. This allowed me to gain 
experience in some of the methods utilized throughout qualitative research, such as 
coding and the use of reflexivity, without becoming overwhelmed. I look forward to 
building on my expertise in qualitative research and exploring the use of other 
methodologies in the future. I also look forward to expanding into the use of quantitative 
methods. 
Finally, this research project has demonstrated to me just how difficult and time-
consuming research can be. Each action required rationalization, consideration of the 
possible outcomes, and comparison with that of alternatives. I have learned that 
anticipating problems and preparing before they arise is absolutely crucial to the success 
of a research project. Collecting high-quality information from interviews posed an 
important challenge. I found that I was focused only on keeping my research participants 
on-topic, and on getting to my next pre-determined question. I hope to be better able to 
remain engaged in the present while conducting interviews in the future, so that I may 
respond to the information coming from participants. This would have been a much more 
effective strategy for ensuring that I collected the appropriate information. The process of 
coding and categorization was also somewhat difficult. I struggled with determining what 
was relevant for answering my research question, and what terms would be appropriate as 
codes or categories. I look forward to practicing these skills in the future and improving 
my ability to conduct high-quality research overall. 
4.5 Conclusions 
In conclusion, understanding the key characteristics of how HCCs are involved in 
CPG development will help in designing this practice so that its benefits are clearly 
articulated and realized. This study utilized qualitative description to provide insight into 
the strategies used in Canada to involve HCCs in the development of CPGs pertaining to 
the management of mood and anxiety disorders. Healthcare consumers have been 
involved throughout CPG development, using strategies that allow these stakeholders to 
provide input into CPG development. Some strategies also allow for ongoing 
communication between professionals and HCCs. Finally, patient resources have been 
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used to provide these stakeholders with information regarding their illnesses and 
additional resources that they may wish to access. Efforts to involve HCCs in CPG 
development are focused on identifying important information that should be 
incorporated into CPGs, but best practices for how this should be done are unclear to 
professionals involved in CPG development.  
Results of this study can be used to design patient and public involvement 
programs for future CPG development initiatives. A better understanding of how HCC 
involvement can lead to the creation of higher-quality CPGs and can help to improve and 
increase efforts to utilize the practice. A greater focus on principles-based reasons for 
HCC involvement is warranted, including the potential to improve democratic decision 
making and achieve patient empowerment. A focus on these principles may help to 
improve the use of HCC involvement in CPG development. In the future, these strategies 
should be evaluated further to determine their effectiveness in incorporating information 
important to patients or even in improving the quality of guidelines being developed.  
 
70 
 
References 
Abelson, J., Forest, P.-G., Eyles, J., Smith, P., Martin, E., & Gauvin, F.-P. (2003). 
Deliberations about deliberative methods: Issues in the design and evaluation of 
public participation processes. Social Science & Medicine, 57(2), 239–251. 
https://doi.org/10.1016/S0277-9536(02)00343-X 
Abelson, J., Li, K., Wilson, G., Shields, K., Schneider, C., & Boesveld, S. (2016). 
Supporting quality public and patient engagement in health system organizations: 
Development and usability testing of the Public and Patient Engagement 
Evaluation Tool. Health Expectations: An International Journal of Public 
Participation in Health Care and Health Policy, 19(4), 817–827. 
https://doi.org/10.1111/hex.12378 
Ahlström, B. H., Skärsäter, I., & Danielson, E. (2011). Children’s View of a Major 
Depression Affecting a Parent in the Family. Issues in Mental Health Nursing, 
32(9), 560–567. https://doi.org/10.3109/01612840.2011.579689 
Albarqouni, L., Doust, J., & Glasziou, P. (2017). Patient preferences for cardiovascular 
preventive medication: A systematic review. Heart, 103(20), 1578–1586. 
https://doi.org/10.1136/heartjnl-2017-311244 
Alonso-Coello, P., Martínez García, L., Carrasco, J. M., Solà, I., Qureshi, S., & Burgers, 
J. S. (2011). The updating of clinical practice guidelines: insights from an 
international survey. Implementation Science: IS, 6, 107. 
https://doi.org/10.1186/1748-5908-6-107 
Alonso-Coello, P., Oxman, A. D., Moberg, J., Brignardello-Petersen, R., Akl, E. A., 
Davoli, M., … Group,  the G. W. (2016). GRADE Evidence to Decision (EtD) 
frameworks: a systematic and transparent approach to making well informed 
healthcare choices. 2: Clinical practice guidelines. BMJ, 353, i2089. 
https://doi.org/10.1136/bmj.i2089 
71 
 
American Academy of Family Physicians. (2017). Clinical practice guideline manual. 
Retrieved from 
file://localhost/Users/AdamJordan/Zotero/storage/D6LZCMQM/cpg-manual.html 
American Psychiatric Association. (2000). Diagnostic and Statistical Manual of Mental 
Disorders IV Text Revision.  
Armstrong, M. J., & Bloom, J. A. (2017). Patient involvement in guidelines is poor five 
years after institute of medicine standards: review of guideline methodologies. 
Research Involvement and Engagement, 3. https://doi.org/10.1186/s40900-017-
0070-2 
Armstrong, M. J., Mullins, C. D., Gronseth, G. S., & Gagliardi, A. R. (2017). 
Recommendations for patient engagement in guideline development panels: A 
qualitative focus group study of guideline-naïve patients. PLoS ONE, 12(3). 
https://doi.org/10.1371/journal.pone.0174329 
Armstrong, M. J., Mullins, C. D., Gronseth, G. S., & Gagliardi, A. R. (2018). Impact of 
patient involvement on clinical practice guideline development: a parallel group 
study. Implementation Science : IS, 13. https://doi.org/10.1186/s13012-018-0745-
6 
Armstrong, M. J., Rueda, J., Gronseth, G. S., & Mullins, C. D. (2017). Framework for 
enhancing clinical practice guidelines through continuous patient engagement. 
Health Expectations : An International Journal of Public Participation in Health 
Care and Health Policy, 20(1), 3–10. https://doi.org/10.1111/hex.12467 
Arnstein, S. R. (2019). A Ladder of Citizen Participation. Journal of the American 
Planning Association, 85(1), 12. 
Ayanian, J. Z., Landrum, M. B., Normand, S.-L. T., Guadagnoli, E., & McNeil, B. J. 
(1998). Rating the appropriateness of coronary angiography — Do practicing 
physicians agree with an expert panel and with each other? New England Journal 
of Medicine, 338(26), 1896–1904. 
https://doi.org/10.1056/NEJM199806253382608 
72 
 
Boivin, A., Currie, K., Fervers, B., Gracia, J., James, M., Marshall, C., … G-I-N 
PUBLIC. (2010). Patient and public involvement in clinical guidelines: 
international experiences and future perspectives. BMJ Quality & Safety, 19(5), 
e22–e22. https://doi.org/10.1136/qshc.2009.034835 
Boivin, Antoine, Green, J., van der Meulen, J., Légaré, F., & Nolte, E. (2009). Why 
consider patients’ preferences?: A discourse analysis of clinical practice guideline 
developers. Medical Care, 47(8), 908. 
https://doi.org/10.1097/MLR.0b013e3181a81158 
Bystritsky, A., Khalsa, S. S., Cameron, M. E., & Schiffman, J. (2013). Current diagnosis 
and treatment of anxiety disorders. Pharmacy and Therapeutics, 38(1), 30–57. 
Camilleri, M., & Parke, D. W. I. (2010). Perspective: Conflict of interest and professional 
organizations: considerations and recommendations. Academic Medicine, 85(1), 
85. https://doi.org/10.1097/ACM.0b013e3181c46429 
Caron-Flinterman, J. F., Broerse, J. E. W., & Bunders, J. F. G. (2007). Patient Partnership 
in Decision-Making on Biomedical Research: Changing the Network. Science, 
Technology, & Human Values, 32(3), 339–368. 
https://doi.org/10.1177/0162243906298354 
Cosoff, S. J., & Julian Hafner, R. (1998). The prevalence of comorbid anxiety in 
schizophrenia, schizoaffective disorder and bipolar disorder. Australian and New 
Zealand Journal of Psychiatry, 32(1), 67–72. https://doi.org/10.1046/j.1440-
1614.1998.00374.x 
Coyne, I. T. (1997). Sampling in qualitative research. Purposeful and theoretical 
sampling; Merging or clear boundaries? Journal of Advanced Nursing, 26, 623-
630. 
Davis, D. A., Goldman, J. B., Palda, V. A., Canadian Medical Association of Ontario, & 
Guidelines Advisory Committee. (2007). Canadian Medical Association 
handbook on clinical practice guidelines. Ottawa, Ont.: Canadian Medical 
Association. Retrieved from http://mdm.ca/cpgsnew/cpgs/index.asp 
73 
 
Detsky, A. S. (2006). Sources of bias for authors of clinical practice guidelines. CMAJ : 
Canadian Medical Association Journal, 175(9), 1033. 
https://doi.org/10.1503/cmaj.061181 
Earl-Slater, A. (2004). Lay involvement in health and other research. Abingdon (UK): 
Radcliffe Medical Press Ltd. 
Elberse, J. E., Caron-Flinterman, J. F., & Broerse, J. E. W. (2011). Patient-expert 
partnerships in research: How to stimulate inclusion of patient perspectives: 
Stimulate inclusion of patient perspectives. Health Expectations, 14(3), 225–239. 
https://doi.org/10.1111/j.1369-7625.2010.00647.x 
Elo, S., Kääriäinen, M., Kanste, O., Pölkki, T., Utriainen, K., & Kyngäs, H. (2014). 
Qualitative content analysis: A focus on trustworthiness. SAGE Open, 4(1), 
215824401452263. https://doi.org/10.1177/2158244014522633 
Elo, S., & Kyngäs, H. (2008). The qualitative content analysis process. Journal of 
Advanced Nursing, 62(1), 107–115. https://doi.org/10.1111/j.1365-
2648.2007.04569.x 
Elwyn, G., Durand, M. A., Song, J., Aarts, J., Barr, P. J., Berger, Z., … Van der Weijden, 
T. (2017). A three-talk model for shared decision making: multistage consultation 
process. The BMJ, 359. https://doi.org/10.1136/bmj.j4891 
Entwistle, V. A., Renfrew, M. J., Yearley, S., Forrester, J., & Lamont, T. (1998). Lay 
perspectives: advantages for health research. BMJ : British Medical Journal, 
316(7129), 463–466. 
Entwistle, V., Calnan, M., & Dieppe, P. (2008). Consumer involvement in setting the 
health services research agenda: Persistent questions of value. Journal of Health 
Services Research & Policy, 13(3_suppl), 76–81. 
https://doi.org/10.1258/jhsrp.2008.007167 
Erlingsson, C., & Brysiewicz, P. (2017). A hands-on guide to doing content analysis. 
African Journal of Emergency Medicine, 7(3), 93–99. 
https://doi.org/10.1016/j.afjem.2017.08.001 
74 
 
Etikan, I., Musa, S. A., & Alkassim, R. S. (2016). Comparison of Convenience Sampling 
and Purposive Sampling. American Journal of Theoretical and Applied Statistics, 
5(1), 1. https://doi.org/10.11648/j.ajtas.20160501.11 
Fickweiler, F., Fickweiler, W., & Urbach, E. (2017). Interactions between physicians and 
the pharmaceutical industry generally and sales representatives specifically and 
their association with physicians’ attitudes and prescribing habits: A systematic 
review. BMJ Open, 7(9), e016408. https://doi.org/10.1136/bmjopen-2017-016408 
Florin, D., & Dixon, J. (2004). Public involvement in health care. BMJ : British Medical 
Journal, 328(7432), 159–161. 
Forsythe, L. P., Ellis, L. E., Edmundson, L., Sabharwal, R., Rein, A., Konopka, K., & 
Frank, L. (2016). Patient and stakeholder engagement in the PCORI Pilot 
Projects: Description and lessons learned. Journal of General Internal Medicine, 
31(1), 13–21. https://doi.org/10.1007/s11606-015-3450-z 
Fraenkel, L., Miller, A., Clayton, K., Crow-Hercher, R., Hazel, S., Johnson, B., … 
Nowell, W. B. (2016). When patients write the guidelines: Patient panel 
recommendations for the treatment of RA. Arthritis Care & Research, 68(1), 26–
35. https://doi.org/10.1002/acr.22758 
Gagné, M. E., Légaré, F., Moisan, J., & Boulet, L.-P. (2017). Impact of adding a decision 
aid to patient education in adults with asthma: A randomized clinical trial. PLoS 
ONE, 12(1). https://doi.org/10.1371/journal.pone.0170055 
GRADE Working Group. (2004). Grading quality of evidence and strength of 
recommendations. British Medical Journal 328(7454). 
doi:10.1136/bmj.328.7454.1490= 
Graham, I., Logan, J., Harrison, M. B., Straus, S. E., Jacqueline T., Caswell, W., & 
Robinson, N. (2006). Lost in knowledge translation: Time for a map? The Journal 
of Continuing Education in the Health Professions, 26(1), 13-24. doi:10.1002/chp 
75 
 
Graneheim, U. H., & Lundman, B. (2004). Qualitative content analysis in nursing 
research: concepts, procedures and measures to achieve trustworthiness. Nurse 
Education Today, 24(2), 105-112. https://doi.org/10.1016/j.nedt.2003.10.001 
Grol, R. (2001). Improving the quality of medical care: Building bridges among 
professional pride, payer profit, and patient satisfaction. Journal of the American 
Medical Association, 286(20), 2578–2585. 
https://doi.org/10.1001/jama.286.20.2578 
Guba, E. G., & Lincoln, Y. S. (1994). Competing paradigms in qualitative research. In 
N.K. Denzin & Y.S. Lincoln (Eds.), Handbook of qualitative research (1st ed., 
pp.105-117). Thousand Oaks, CA: Sage. 
Guidelines International Network Public Working Group. (2015). G-I-N Public toolkit: 
Patient and public involvement in guidelines. Retrieved from https://www.g-i-
n.net/document-store/working-groups-documents/g-i-n-public/toolkit/toolkit-2015 
Health Council of Canada. (2012). Understanding clinical practice guidelines: A video 
series primer. Toronto, ON: Health Council of Canada. Retrieved from: 
https://healthcouncilcanada.ca/files/CPG_Backgrounder_EN.pdf.pdf 
Hogg, C., & Williamson, C. (2001). Whose interests do lay people represent? Towards an 
understanding of the role of lay people as members of committees. Health 
Expectations : An International Journal of Public Participation in Health Care 
and Health Policy, 4(1), 2–9. https://doi.org/10.1046/j.1369-6513.2001.00106.x 
Hsieh, H.-F., & Shannon, S. E. (2005). Three approaches to qualitative content analysis. 
Qualitative Health Research, 15(9), 1277–1288. 
https://doi.org/10.1177/1049732305276687 
Institute of Medicine. (2009). Conflict of interest in medical research, education, and 
practice. (B. Lo & M. J. Field, Eds.). Washington (DC): National Academies 
Press (US). Retrieved from http://www.ncbi.nlm.nih.gov/books/NBK22942/ 
76 
 
Institute of Medicine. (2011). Clinical practice guidelines we can trust. Washington 
(DC): National Academic Pres (US). Retrieved from https://www-ncbi-nlm-nih-
gov.proxy1.lib.uwo.ca/pubmedhealth/PMH0079468/ 
Jansen, J., McKinn, S., Bonner, C., Irwig, L., Doust, J., Glasziou, P., … McCaffery, K. 
(2015). Systematic review of clinical practice guidelines recommendations about 
primary cardiovascular disease prevention for older adults. BMC Family Practice, 
16. https://doi.org/10.1186/s12875-015-0310-1 
Kessler, R. C., Birnbaum, H., Shahly, V., Bromet, E., Hwang, I., McLaughlin, K. A., … 
Stein, D. J. (2010). Age differences in the prevalence and comorbidity of DSM-IV 
major depressive episodes: Results from the WHO World Mental Health Survey 
Initiative. Depression and Anxiety, 27(4), 351–364. 
https://doi.org/10.1002/da.20634 
Lai, H. M. X., Cleary, M., Sitharthan, T., & Hunt, G. E. (2015). Prevalence of comorbid 
substance use, anxiety and mood disorders in epidemiological surveys, 1990–
2014: A systematic review and meta-analysis. Drug and Alcohol Dependence, 
154, 1–13. https://doi.org/10.1016/j.drugalcdep.2015.05.031 
Lavis, J. N., Paulsen, E. J., Oxman, A. D., & Moynihan, R. (2008). Evidence-informed 
health policy 2 – Survey of organizations that support the use of research 
evidence. Implementation Science : IS, 3, 54. https://doi.org/10.1186/1748-5908-
3-54 
Légaré, F., Boivin, A., van der Weijden, T., Pakenham, C., Burgers, J., Légaré, J., … 
Gagnon, S. (2011). Patient and public involvement in clinical practice guidelines: 
A knowledge synthesis of existing programs. Medical Decision Making, 31(6), 
E45–E74. https://doi.org/10.1177/0272989X11424401 
Légaré, F., Boivin, A., van der Weijden, T., Packenham, C., Tapp, S., & Burgers, J. 
(2009). A knowledge synthesis of patient and public involvement in clinical 
practice guidelines: Study protocol. Implementation Science : IS, 4, 30. 
https://doi.org/10.1186/1748-5908-4-30 
77 
 
Lindsay, M. P., Gubitz, G., Bayley, M., Hill, M. D., Phillips, S., & Smith, E. E. (2014). 
Canadian stroke best practice recommendations overview and methodology. 
Ottawa, ON: Heart and Stroke Foundation, Canada. 
Lund Research. (2010). Total Population Sampling. Retrieved from: 
http://dissertation.laerd.com/total-population-sampling.php 
Mallik, M. (1997). Patient representatives: a new role in patient advocacy. British 
Journal of Nursing (Mark Allen Publishing), 6(2), 108–113. 
https://doi.org/10.12968/bjon.1997.6.2.108 
McHugh, R. K., Whitton, S. W., Peckham, A. D., Welge, J. A., & Otto, M. W. (2013). 
Patient preference for psychological vs. pharmacological treatment of psychiatric 
disorders: A meta-analytic review. The Journal of Clinical Psychiatry, 74(6), 
595–602. https://doi.org/10.4088/JCP.12r07757 
McRae, L., O’Donnell, S., Loukine, L., Rancourt, N., & Pelletier, C. (2016). Report 
summary - mood and anxiety disorders in Canada, 2016. Health Promotion and 
Chronic Disease Prevention in Canada : Research, Policy and Practice, 36(12), 
314–315. 
Milne, J., & Oberle, K. (2005). Enhancing rigor in qualitative description. Journal of 
Wound, Ostomy and Continence Nursing, 32(6), 413-420.  
Mühlbacher, A. C., & Juhnke, C. (2013). Patient preferences versus physicians’ 
judgement: Does it make a difference in healthcare decision making? Applied 
Health Economics and Health Policy, 11(3), 163–180. 
https://doi.org/10.1007/s40258-013-0023-3 
Neergaard, M. A., Olesen, F., Andersen, R. S., & Sondergaard, J. (2009). Qualitative 
description – the poor cousin of health research? BMC Medical Research 
Methodology, 9(52). https://doi.org/10.1186/1471-2288-9-52 
Neuman, J., Korenstein, D., Ross, J. S., & Keyhani, S. (2011). Prevalence of financial 
conflicts of interest among panel members producing clinical practice guidelines 
78 
 
in Canada and United States: cross sectional study. The BMJ: British Medical 
Journal, 343. https://doi.org/10.1136/bmj.d5621 
Nilsen, E. S., Myrhaug, H. T., Johansen, M., Oliver, S., & Oxman, A. D. (2006). 
Methods of consumer involvement in developing healthcare policy and research, 
clinical practice guidelines and patient information material. The Cochrane 
Database of Systematic Reviews, (3), CD004563. 
https://doi.org/10.1002/14651858.CD004563.pub2 
Ontario Medical Association. (June, 2010). Patient centered care. Ontario Medical 
Review, 34-49. 
Pearce, J.C. (1971). The crack in the cosmic egg: Challenging constructs of mind and 
reality. New York: Washington Square Press. 
Public Health Agency of Canada (2016, May 27). Report from the Canadian Chronic 
Disease Surveillance System: Mood and anxiety disorders in Canada. Retrieved 
from https://www.canada.ca/en/public-health/services/publications/diseases-
conditions/report-canadian-chronic-disease-surveillance-system-mood-anxiety-
disorders-canada-2016.html 
Qaseem, A., Forland, F., Macbeth, F., Ollenschläger, G., Phillips, S., van der Wees, P., 
Board of Trustees of the Guidelines International Network. (2012). Guidelines 
International Network: toward international standards for clinical practice 
guidelines. Annals of Internal Medicine, 156(7), 525–31. 
Rashid, A., Thomas, V., Shaw, T., & Leng, G. (2017). Patient and Public Involvement in 
the Development of Healthcare Guidance: An Overview of Current Methods and 
Future Challenges. The Patient - Patient-Centered Outcomes Research, 10(3), 
277–282. https://doi.org/10.1007/s40271-016-0206-8 
Roberge, P., Hudon, C., Pavilanis, A., Beaulieu, M.-C., Benoit, A., Brouillet, H., … 
Vanasse, A. (2016). A qualitative study of perceived needs and factors associated 
with the quality of care for common mental disorders in patients with chronic 
79 
 
diseases: the perspective of primary care clinicians and patients. BMC Family 
Practice, 17(1). https://doi.org/10.1186/s12875-016-0531-y 
Roberts, L. W., & Kim, J. P. (2016). Are individuals living with mental illness and their 
preferred alternative decision-makers aligned in their attitudes regarding treatment 
decisions? Journal of Psychiatric Research, 78, 42–47. 
https://doi.org/10.1016/j.jpsychires.2016.03.004 
Roth, D. (2011). A third seat at the table: An insider’s perspective on patient 
representatives. Hastings Center Report, 41(1), 29–31. 
https://doi.org/10.1002/j.1552-146X.2011.tb00097.x 
Rowe, G., & Frewer, L. J. (2005). A typology of public engagement mechanisms. 
Science, Technology, & Human Values, 30(2), 251–290. 
https://doi.org/10.1177/0162243904271724 
Salkind, N. J. (2010). Encyclopedia of research design: Naturalistic inquiry. SAGE 
Reference, 881-885. http://dx.doi.org/10.4135/9781412961288.n262 
Sandelowski, M. (2000). Whatever happened to qualitative description? Research in 
Nursing & Health, 23(4), 334–340. https://doi.org/10.1002/1098-
240X(200008)23:4<334::AID-NUR9>3.0.CO;2-G 
Sandelowski, M. (2010). What's in a name? Qualitative description revisited. Research in 
Nursing and Health, 33, 77-84. 
Schatz, D. B., & Rostain, A. L. (2006). ADHD With Comorbid Anxiety: A Review of the 
Current Literature. Journal of Attention Disorders, 10(2), 141–149. 
https://doi.org/10.1177/1087054706286698 
Scott, E. M., Hermens, D. F., Naismith, S. L., Guastella, A. J., De Regt, T., White, D., … 
Hickie, I. B. (2013). Distinguishing young people with emerging bipolar disorders 
from those with unipolar depression. Journal of Affective Disorders, 144(3), 208–
215. https://doi.org/10.1016/j.jad.2012.06.031 
80 
 
Scott, I. A., & Guyatt, G. H. (2011). Clinical practice guidelines: the need for greater 
transparency in formulating recommendations. The Medical Journal of Australia, 
195(1), 29–33. 
Shekelle, P. G., Ortiz, E., Rhodes, S., Morton, S. C., Eccles, M. P., Grimshaw, J. M., & 
Woolf, S. H. (2001). Validity of the Agency for Healthcare Research and Quality 
clinical practice guidelines: how quickly do guidelines become outdated? Journal 
of the American Medical Association, 286(12), 1461–1467. 
Shrier, I., Boivin, J.-F., Platt, R. W., Steele, R. J., Brophy, J. M., Carnevale, F., … 
Rossignol, M. (2008). The interpretation of systematic reviews with meta-
analyses: an objective or subjective process? BMC Medical Informatics and 
Decision Making, 8, 19. https://doi.org/10.1186/1472-6947-8-19 
Stacey, D., Légaré, F., Col, N. F., Bennett, C. L., Barry, M. J., Eden, K. B., … Wu, J. H. 
(2014). Decision aids for people facing health treatment or screening decisions. 
Cochrane Database of Systematic Reviews, (1). 
https://doi.org/10.1002/14651858.CD001431.pub4 
Straus, S. E., Tetroe, J., & Graham, I. (2009). Defining knowledge translation. Canadian 
Medical Association Journal, 181(3-4), 165-168. doi:10.1503/cmaj.081229 
Suri, H. (2011). Purposeful sampling in qualitative research synthesis. Qualitative 
Research Journal, 11(2). doi:10.3316/QRJ1102063 
Swinson, R. P., Antony, M. M., Bleau, P., Chokka, P., Craven, M., Fallu, A., … Stein, D. 
J. (2006). Management of anxiety disorders. Canadian Journal of Psychiatry, 51, 
92. 
Taddio, A., Shah, V., Leung, E., Wang, J., Parikh, C., Smart, S., … Franck, L. (2013). 
Knowledge translation of the HELPinKIDS clinical practice guideline for 
managing childhood vaccination pain: usability and knowledge uptake of 
educational materials directed to new parents. BMC Pediatrics, 13, 23. 
https://doi.org/10.1186/1471-2431-13-23 
81 
 
Tong, A., Lopez-Vargas, P., Howell, M., Phoon, R., Johnson, D., Campbell, D., … Craig, 
J. C. (2012). Consumer involvement in topic and outcome selection in the 
development of clinical practice guidelines: Consumer involvement in guideline 
development. Health Expectations, 15(4), 410–423. 
https://doi.org/10.1111/j.1369-7625.2011.00676.x 
Tracy, S. J. (2010). Qualitative quality: Eight “big tent” criteria for excellent qualitative 
research. Qualitative Inquiry, 16(10), 837-851. doi:10.1177/1077800410383121 
UK Essays. (November 2013). Theoretical Perspective Constructivism And Naturalistic 
Inquiry Psychology Essay. Retrieved from 
https://www.ukessays.com/essays/psychology/theoretical-perspective-
constructivism-and-naturalistic-inquiry-psychology-essay.php?vref=1 
Vaismoradi, M., Turunen, H., & Bondas, T. (2013) Content analysis and thematic 
analysis: Implications for conducting a qualitative descriptive study. Nursing and 
Health Sciences, 15, 398-405. doi:10.1111/nhs.12048 
van de Bovenkamp, H. M., & Trappenburg, M. J. (2009). Reconsidering Patient 
Participation in Guideline Development. Health Care Analysis, 17(3), 198–216. 
https://doi.org/10.1007/s10728-008-0099-3 
van de Bovenkamp, H. M., & Zuiderent‐Jerak, T. (2015). An empirical study of patient 
participation in guideline development: exploring the potential for articulating 
patient knowledge in evidence‐based epistemic settings. Health Expectations : An 
International Journal of Public Participation in Health Care and Health Policy, 
18(5), 942–955. https://doi.org/10.1111/hex.12067 
van Wersch, A., & Eccles, M. (2001). Involvement of consumers in the development of 
evidence based clinical guidelines: practical experiences from the North of 
England evidence based guideline development programme. Quality in Health 
Care, 10(1), 10–16. https://doi.org/10.1136/qhc.10.1.10 
82 
 
Wait, S., & Nolte, E. (2006). Public involvement policies in health: exploring their 
conceptual basis. Health Economics, Policy and Law, 1(02), 149. 
https://doi.org/10.1017/S174413310500112X 
Western University. (2017a). Data Security and Confidentiality. Retrieved from 
file:///Users/AdamJordan/Downloads/Data%20Security%20and%20Confidentialit
y-Guidance%20Document%20(21Aug2017)%20(6).pdf 
Western University. (2017b). Letter of Information and Consent Guidance Document. 
Retrieved from 
file:///Users/AdamJordan/Downloads/NMREB%20Letter%20of%20Information
%20and%20Consent%20Guidance%20Document%20(v13Sept2018).pdf 
Western University. (2019). Goals & Objectives. Retrieved from: 
https://www.fims.uwo.ca/programs/graduate_programs/master_of_health_inform
ation_science/goals_objectives.html 
Williamson, C. (1998). The rise of doctor-patient working groups. BMJ : British Medical 
Journal, 317(7169), 1374–1377. 
Williamson, C. (1999). Reflections on health care consumerism: insights from feminism. 
Health Expectations : An International Journal of Public Participation in Health 
Care and Health Policy, 2(3), 150–158. https://doi.org/10.1046/j.1369-
6513.1999.00043.x 
Woolf, S. H., Grol, R., Hutchinson, A., Eccles, M., & Grimshaw, J. (1999). Potential 
benefits, limitations, and harms of clinical guidelines. BMJ : British Medical 
Journal, 318(7182), 527–530. 
World Health Organization. (2008). Health Information Systems. Retrieved from: 
https://www.who.int/healthinfo/statistics/toolkit_hss/EN_PDF_Toolkit_HSS_Info
rmationSystems.pdf 
World Health Organization. (2010). WHO handbook for guideline development. Retrieved 
from http://www.who.int/hiv/topics/mtct/grc_handbook_mar2010_1.pdf 
83 
 
World Health Organization. (2014). Handbook for guideline development (2nd ed.). 
Retrieved from 
http://apps.who.int/medicinedocs/documents/s22083en/s22083en.pdf 
Yebyo, H. G., Aschmann, H. E., Yu, T., & Puhan, M. A. (2018). Should statin guidelines 
consider patient preferences? Eliciting preferences of benefit and harm outcomes 
of statins for primary prevention of cardiovascular disease in the sub-Saharan 
African and European contexts. BMC Cardiovascular Disorders, 18. 
https://doi.org/10.1186/s12872-018-0838-9 
84 
 
Appendices 
Appendix A: Terms Used to Search PubMed 
Initial Search Term: 
((canada OR canadian OR canad* OR nova scotia OR ontario OR pei OR prince edward 
island OR british columbia OR new brunswick OR quebec OR newfoundland OR 
labrador OR Manitoba OR Saskatchewan OR Alberta OR Yukon OR Nunavut OR 
Northwest)) 
Combined with One of: 
(((((((((guideline[ti] OR guidelines[ti]))) AND (((anxiety disorders OR anxiety disorder)) 
OR (mood disorders OR mood disorder)))))) 
This combined search term displayed 73 results. 
(((((anxiety disorders OR anxiety disorder)) OR (mood disorders OR mood disorder)) 
AND ((Guideline[ptyp] OR Practice Guideline[ptyp])))))) 
This combined search term displayed 10 results. 
(((((anxiety disorders OR anxiety disorder)) OR (mood disorders OR mood disorder))) 
AND guidelines as topic[mesh]) 
This combined search term displayed 58 results. 
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Appendix A: Clinical Practice Guidelines Relevant for Analysis 
Antidepressants in Elderly Patients with Major and Minor Depression: A Review of 
Clinical Effectiveness and Guidelines 
Affiliated Organization: Canadian Agency for Drugs and Technologies in Health 
Date of Publication: August 17, 2015 
 
Best Practice Guidelines for Mental Health Disorders in the Perinatal Period 
Affiliated Organizations: Provincial Health Services Authority British Columbia (BC 
Mental Health and Substance Use Services, Perinatal Services BC), British Columbia 
Ministry of Health 
Date of Publication: March, 2014 
 
Canadian Clinical Practice Guidelines for the Management of Anxiety, Posttraumatic 
Stress and Obsessive-Compulsive Disorders 
Affiliated Organizations: Anxiety Disorders Association of Canada, McGill University 
Date of Publication: July 2, 2014 
 
CANMAT 2016 Clinical Guidelines for the Management of Adults with Major 
Depressive Disorder (Series) 
Affiliated Organizations: Canadian Network for Mood and Anxiety Treatments 
Date of Publication: August 2, 2016 
 
CANMAT and ISBD 2018 Guidelines for the Management of Patients with Bipolar 
Disorder 
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Affiliated Organizations: Canadian Network for Mood and Anxiety Treatments, 
International Society for Bipolar Disorders 
Date of Publication: April 21, 2018 
 
Depression in Multiple Sclerosis Clinical Practice Guideline 
Affiliated Organizations: Towards Optimized Practice 
Date of Publication: December, 2015 
 
Major Depressive Disorder in Adults: Diagnosis and Management 
Affiliated Organizations: Guidelines and Protocols Advisory Committee, British 
Columbia Ministry of Health, Doctors of British Columbia (formerly British Columbia 
Medical Association) 
Date of Publication: December 15, 2013 
 
Maternal Depression and Child Development 
Affiliated Organizations: Canadian Paediatric Society (Mental Health and Developmental 
Disabilities Committee) 
Date of Publication/Updating: January 30, 2015 
 
Recommendations on Screening for Depression in Adults 
Affiliated Organizations: Canadian Task Force for Preventive Health Care 
Date of Publication: June 11, 2013 
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The Assessment and Treatment of Mental Health Issues in Long Term Care Homes: 
(Focus on Mood and Behaviors Symptoms) 
Affiliated Organizations: Canadian Coalition for Seniors’ Mental Health 
Date of Publication/Updating: 2014 
 
The Management of Depression in Patients with Cancer 
Affiliated Organizations: Cancer Care Ontario (Program in Evidence-Based Care) 
Date of Publication: May 11, 2015 
 
Use of Selective Serotonin Reuptake Inhibitor Medications for the Treatment of Child 
and Adolescent Mental Illness 
Affiliated Organizations: Canadian Paediatric Society (Mental Health & Developmental 
Disabilities Committee) 
Date of Publication/Updating: February 1, 2016 
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Appendix C: Email Script for Study Recruitment 
Subject Line: Request for participation in research  
Hello, 
**An email was sent to you two weeks ago and I wanted to send you a quick reminder 
about my study.** 
My name is Adam Jordan, and I am a Master of Health Information Science student at 
Western University in Ontario, Canada. I have collected your email address from the 
clinical practice guideline titled respective CPG title published by organization name. As 
a listed corresponding author for this publication, you are being invited to participate in a 
study that I, Adam Jordan, am conducting at Western University for the Master of Health 
Information Science program, under the supervision of Dr. Jaquelyn Burkell. Briefly, this 
study involves characterizing the involvement of health care consumers in the 
development of clinical practice guidelines for mood and anxiety disorders. As a 
corresponding author for a guideline being considered in my research, you will be asked 
to participate in an interview focusing on the involvement of patients or other members of 
the public in the development of the relevant guideline. Answering these questions 
should take twenty to thirty minutes. If you are unable or unwilling to commit to 
scheduling an interview, you may also request that a secure link to an online 
questionnaire be sent to you via email. This questionnaire will also contain questions 
surrounding the involvement of patients or other members of the public in the 
development of the relevant clinical practice guideline. 
If you believe there is a different professional involved in the development of this 
guideline who would be better able to answer questions related to the material outlined 
above, please forward this email to them. 
If you would like to schedule an interview, request a questionnaire, or would like more 
information on this study, please contact the researcher at the contact information given 
below. 
 
*If the researcher does not receive a response to this email within 2 weeks of it being 
sent, a reminder email will be sent. One attempt to contact potential participants via 
telephone will be made if the researcher is unable to establish a connection through 
email.* 
**If the researcher does not receive a response to this email within one week of it being 
sent, one attempt to contact the potential participant via telephone will be made.** 
Kind regards, 
Adam Jordan 
Email Redacted 
Phone Number Redacted 
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Master of Health Information Science student 
Western University 
*To be included in initial email only.* 
**To be included in reminder email only.** 
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Appendix D: Telephone Recruitment Script 
Hello, may I speak with respective participant’s name? 
Hi, respective participant’s name, my name is Adam Jordan, and I am a master of Health 
Information Science student at Western University. I am calling today to see if you are 
interested in a research study I am conducting. This research is being conducted by 
myself under the supervision of Dr. Jacquelyn Burkell from Western University’s Faculty 
of Information and Media Studies. This study will look at how patients and other 
members of the public are involved in the development of clinical practice guidelines in 
Canada. Your participation would entail answering questions regarding how these 
stakeholders were involved in the development of respective title of clinical practice 
guideline, as you have been identified as a corresponding author for this publication. 
Answering these questions over the phone is estimated to take twenty to thirty minutes. 
Would you be interested in hearing more about this study at the present time?  
*If no, present opportunity to schedule a call-back. If the participant is still not interested, 
ask if they are aware of another author who may be better suited to participate in the 
interview. If so, ask that they forward the recruitment email to them, thank them for their 
time and hang up* 
*If yes, continue to explain study details to them based on the letter of information* 
I am now going to read over our letter of information over the phone. This letter of 
information has also been provided to you through email. *read letter of information to 
participant* 
Do you have any questions? 
Do you agree to participate in this study by being interviewed at the present time? 
*If no, present the opportunity to schedule the interview for a better time. If the 
participant is still not interested, present opportunity to complete questionnaire. If the 
participant is still not interested, thank them for their time and hang up.* 
 
*Questions below will be asked and boxes will be checked off for each participant who 
agrees to be interviewed* 
Do you confirm that you have read the Letter of Information [or the Letter of Information 
has been read to you] and have had all questions answered to your satisfaction? 
 YES  NO 
 
Do you agree to participate in this research? 
 YES  NO 
Do you agree to be audio-recorded?  
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 YES  NO 
 
Do you consent to the use of unidentified quotes obtained during the study in the 
dissemination of this research?  
 YES  NO 
*If the participant prefers to complete the questionnaire, proceed with explaining how 
this process should work* 
I can provide you with the letter of information and consent, and a link to the online 
questionnaire though email. I have collected your email from a public source, namely the 
corresponding author information given for the clinical practice guideline relevant 
clinical practice guideline title.  
Do you have any other questions? 
*If no, thank them for their time and end call* 
*If yes, answer questions, thank participant for their time and end call* 
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Appendix E: Letter of Information and Consent 
Principal Investigator 
Dr. Jaquelyn Burkell, Assistant Dean, Research 
Faculty of Information and Media Studies 
Western University 
Phone Number Redacted 
Email Redacted 
Co-Investigator 
Adam Jordan, Master’s Student, Health Information Science 
Western University 
Phone Number Redacted 
Email Redacted 
Introduction 
You are being invited to participate in a research study which seeks to characterize the 
methods used to involve patients and other members of the public in the development of 
clinical practice guidelines. You are being invited because you have been identified as a 
corresponding author for one of the clinical practice guidelines which was selected for 
analysis in this study. Your knowledge of the methods used to develop this clinical 
practice guideline will be important for this study. 
Involving patients and other members of the public in the development of clinical 
practice guidelines has been shown to have positive effects on the scope of these 
documents. How these stakeholders are being involved in the development of Canadian 
clinical practice guidelines is poorly studied. The purpose of this study is to characterize 
the methods used to involve patients and other members of the public in the development 
of clinical practice guidelines in Canada. Specifically, guidelines pertaining to the 
management of mood and anxiety disorders will be analyzed. This will allow for current 
practices in Canada to be compared to national and international recommendations. 
Collecting this information will also allow for future analysis of the effectiveness of the 
methods being used.  
If you agree to participate in this study, you will be interviewed. During this interview, 
you will be asked to comment on the methods or procedures used to involve patients or 
other members of the public throughout the development of the respective clinical 
practice guideline in which you took part. The interview will be completed over the 
telephone and is anticipated to take twenty to thirty minutes. With your permission, the 
telephone call will be recorded to allow for transcription.  
If you are unable to commit to scheduling an interview, you may still participate in this 
study through filling out a questionnaire. The questionnaire will also ask you to comment 
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on the methods or procedures used to involve patients or other members of the public 
throughout the development of the respective clinical practice guideline in which you 
took part. This questionnaire will be provided through Qualtrics, and a secure link to this 
questionnaire will be provided to you via email at your request. You will also be provided 
with a unique study ID. This ID should be entered when prompted by the questionnaire, 
to allow collected information to remain identifiable to the researchers only. The 
questionnaire is anticipated to take twenty to thirty minutes to complete. 
There are no known or anticipated risks associated with participating in this study. You 
may not directly benefit from the results of this study; however, the results may bring to 
light current practice in Canada regarding the development of clinical practice guidelines. 
This is a critical first step in analyzing the effectiveness of current practice so that it may 
be improved in the future in an attempt to make clinical practice guidelines more relevant 
to the patients whose care they affect.  
If you wish to withdraw from this study in the future, you have the right to request the 
withdrawal of information collected from you. Please let the researcher know if you wish 
to have your information removed, using the contact information given below. 
Your contact information has been collected from a public source, namely the 
corresponding author information given in a clinical practice guideline being analyzed in 
this study. Any information collected from you will not be connected back to the related 
clinical practice guideline. Your name will be replaced with a pseudonym for the 
purposes of data analysis and reporting (different from the aforementioned study ID), and 
any further identifying information will be removed from data collected during the 
interview or questionnaire process. Any publications resulting from this study will not 
use your name or other identifying information. 
Representatives of The University of Western Ontario Non-Medical Research Ethics 
Board may require access to your study-related records to monitor the conduct of the 
research.   
While the researcher for this study will do their best to protect your information there is 
no guarantee that they will be able to do so. If any information collected during this study 
is required to be reported by law, the researcher will have a duty to report.  
The researcher will keep any personal information collected about you in a secure and 
confidential location for a minimum of seven years. Information collected for analysis 
will be stored electronically on an encrypted and password protected flash drive, in line 
with Western University’s Data Security Guidelines. A list linking your pseudonym with 
your name will be kept by the researcher in a secure place, separate from the study file. 
You will not be compensated for your participation in this study. 
Your participation in this study is voluntary. You may decide not to be in this study.  
Even if you consent to participate you have the right to not answer individual questions 
or to withdraw from the study at any time.  If you choose not to participate or to leave the 
study at any time it will have no effect on your relationship with the researcher or 
professional endeavors. You will be updated with new information gathered throughout 
the study which may affect your decision to stay in the study. 
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You do not waive any legal right by agreeing to participate in this study. 
If you have any questions about this study please contact: 
Dr. Jaquelyn Burkell, Assistant Dean, Research 
Faculty of Information and Media Studies 
Western University 
Phone Number Redacted 
Email Redacted 
Or 
Adam Jordan, Master’s Student, Health Information Science 
Western University 
Phone Number Redacted 
Email Redacted 
If you have any questions about your rights as a research participant or the conduct of this 
study, you may contact: 
The Office of Human Research Ethics  
Phone Number Redacted 
Toll free: Phone Number Redacted 
email: Email Redacted 
In the case that you prefer to complete the questionnaire, you indicate your voluntary 
agreement to participate by responding to the questionnaire which will be provided to 
you as an attachment through email. 
This letter is yours to keep for future reference. 
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Appendix F: Interview Guide 
1. Were patients involved in the development of respective guideline title? 
 
If yes, please describe how they were involved (eg the stage of guideline 
development during which they were involved, the methods used, and for 
what purposes they were involved). 
Can you describe the decision making process? 
If no, was involving patients in the development of this guideline ever 
considered?  
 
2. Were other groups of lay persons or patient representatives involved in the 
development of this guideline? 
 
If yes, please describe how they were involved (eg the stage of guideline 
development during which they were involved, the methods used, and for 
what purposes they were involved). 
Can you describe the decision making process? 
If no, was involving other groups of lay persons in the development of this 
guideline ever considered? Why was it avoided? 
 
3. What do you see as the value in involving patients or other members of the public 
in clinical practice guideline development? 
 
4. What are some potential challenges, or challenges that you have already identified 
in involving patients or other members of the public in clinical practice guideline 
development? 
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Appendix G: Survey Questions 
Patient Involvement in Clinical Practice 
Guideline Development 
 
Start of Block: Question 1 
Q1 Please provide your unique study ID (provided in the email through which you 
accessed this questionnaire). 
________________________________________________________________ 
End of Block: Question 1 
 
Start of Block: Question 2 
Qa Were patients involved in the development of the clinical practice guideline in 
question? 
________________________________________________________________ 
Qb If yes, please describe how they were involved (eg the stage of guideline development 
during which they were involved, the methods used, and for what purposes they were 
involved). 
________________________________________________________________ 
Qc If no, was involving patients in the development of this guideline ever considered? 
Why was it avoided? 
________________________________________________________________ 
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End of Block: Question 2 
 
Start of Block: Question 3 
Qa Were other groups of lay persons or patient representatives involved in the 
development of this guideline? 
________________________________________________________________ 
Qb  
If yes, please describe how they were involved (eg the stage of guideline development 
during which they were involved, the methods used, and for what purposes they were 
involved). 
________________________________________________________________ 
Qc  
If no, was involving other groups of lay persons in the development of this guideline ever 
considered? Why was it avoided? 
________________________________________________________________ 
End of Block: Question 3 
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Appendix H: Summary of Reflexive Notes 
This section of the appendices presents summaries of the reflexive notes taken 
while this study was being carried out. These notes include my reflections on challenges 
encountered, and how my interactions with the dataset could have impacted the results of 
this study. To begin, I tried to encourage participation in my study by indicating that 
information collected in this study would be used only to describe strategies being used to 
involve HCCs in CPG development, and not to evaluate these strategies. However, it was 
also indicated that the results from this study could be used to evaluate these strategies in 
the future, to either improve on them or identify what methods work most effectively for 
the purported benefits. I think my research participants were able to give well informed 
and genuine answers to my questions. However, it is possible that knowledge of future 
plans to evaluate strategies being used impacted the information provided by participants. 
Participants may have been eager to describe instances of HCC involvement even outside 
of CPG development, and used information from these cases to describe the value of 
HCC involvement in CPG development specifically. Furthermore, it is possible that 
participants chose not to focus on the challenges encountered, but to focus on the possible 
benefits instead, in order to cast efforts in a positive light. I do not believe this affected 
the honesty their answers, but only the level of detail provided for the benefits versus the 
challenges encountered. The challenges associated with HCC involvement were still 
reported on in some cases. Additionally, participants indicated that only patients were 
involved in CPG development, and were reluctant to comment on the value of involving 
other groups of HCCs. It is likely this was due only to a lack of experience with involving 
other groups of HCCs. 
Conducting interviews was strenuous, and, in retrospect, I missed opportunities to 
delve into detail on certain topics with my research participants. I tried to stay on topic as 
much as possible, in order to adhere to the research outline I had submitted for ethics 
approval. I also wanted to respect the time my research participants had taken from their 
work to dedicate to this study. Resultantly, I followed my interview guide very strictly. I 
therefore missed opportunities to explore ideas brought up by my research participants, 
such as plans for future involvement strategies, or details regarding quality improvement 
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strategies that involve CPG development. I also noticed that I was distracted by my note 
taking and backreferencing to materials I had collected to prepare for my interviews. This 
may have resulted in some confusion between my research participants and myself and 
hindered their ability to fully answer my questions in some cases. 
Additionally, my interactions with web-based data sources utilized in this study 
are worth mentioning. The process of extracting meaning units and codes from the data 
sources utilized in this study required some interpretation. In many cases, it was not clear 
how to code certain pieces of information. For example, some terms used to describe 
important factors of HCC involvement were ambiguous and required me to make a 
decision in regard to how I would code the information. For example, the use of the term 
“community member” could have implied that members of the general public were 
involved in a particular strategy being described. However, this term referred to both 
“older adults” and “service providers”. Because “older adults” were interpreted to be the 
population who’s care this CPG pertained to, “older adults” was interpreted to refer to 
patients. Furthermore, “service providers” was interpreted as referring to professional 
healthcare providers, in the absence of a direct definition for this term within the data 
source. The term “community member” was therefore interpreted to included 
professional stakeholders, meaning that it could not be interpreted as meaning only 
members of the general public. 
Finally, many of the data sources analyzed for this study referenced patient and 
public involvement strategies used outside of CPG development. Much of this 
information contained insight into the value of patient and public involvement initiatives, 
and descriptions of how these initiatives were utilized. However, none of these pertained 
directly to the development of CPGs. This information has not been considered as 
relevant for reporting in this study, unless it could be explicitly linked to the process of 
CPG development. This information was still reviewed in full to ensure appropriate 
decisions were made regarding its relevance. There was a focus on the promotion of 
patient-centered care within descriptions of these patient and public involvement 
initiatives. This focus on patient-centered care within the organizations that develop 
CPGs may have influenced the discourse surrounding HCC involvement in CPG 
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development within these organizations, and likewise the information provided by 
professionals from these organizations during interviews. The focus on patient-centered 
care in these materials could have also influenced my own interpretations of data sources 
when deciphering what material was describing how CPGs are developed. 
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Appendix I: Ethics Approval Form 
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